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Abstract
DAX-1 (Dosage-sensitive sex reversal, adrenal hypoplasia congenita, critical region
on the X-chromosome, gene 1) is an unusual member of the Nuclear Hormone Receptor
superfamily that has the ability to interact with other Nuclear Receptors (NRs) and
transcriptional co-repressors and co-activators. While DAX-1 plays an important role in
adrenal and gonadal development, recent studies have elucidated the role DAX-1 plays as a
transcriptional repressor and its influence on the progression of different types of cancers.
The primary aim of this thesis research project is to investigate the role of non-aromatizable
androgens in inducing DAX-1 expression and to determine how DAX-1 influences
proliferation, apoptosis, and metastasis in prostate cancer cells. Using a non-aromatizable
androgen, we were able to analyze DAX-1 expression in Androgen Receptor (AR) positive
and negative prostate cancer cell lines. We also performed chromatin immunoprecipitation
to ascertain if the AR protein plays a role in the transcriptional regulation of the DAX-1
gene. Through these assays, we were able to analyze the link between AR and DAX-1
expression in the context of prostate cancer. In an attempt to understand how AR and DAX1 influence proliferation, apoptosis, and metastasis in prostate cancer cells, we analyzed
different target genes involved in these pathways as well as their effects in proliferation,
apoptosis, and metastasis rates after treatment with a non-aromatizable androgen. Transient
transfections of DAX-1 and CRISPR-Cas9 knock out of DAX-1were used to understand
the effects of DAX-1 in regulating proliferation, apoptosis, and metastasis. Results showed
that DAX-1 plays a central role in regulating genes pivotal for proliferation, apoptosis, and
metastasis in prostate cancer cells. These results exposed the complexity of cancer biology
in prostate cancer cell progression, as well as a deeper understanding of how transcriptional
repressors such as DAX-1 can influence the progression of certain types of cancers.
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Chapter 1
Prostate Cancer, Nuclear Hormone Receptors, and DAX-1
Introduction
Prostate cancer (PCa) is the most commonly diagnosed cancer and the third leading
cause of cancer death in men of all races in the United States [1]. The normal development
and maintenance of the prostate gland tissues as well as prostate cancer is dependent upon
androgens acting on the androgen receptor (AR). Therefore, the main course of treatment
for prostate cancer is androgen-deprivation therapy (ADT). However, ADT ultimately fails
in a number of patients, and prostate cancer recurs in a more aggressive androgenindependent state known as castration-resistant prostate cancer (CRPC) [2]. CRPC is a
hormone-refractory state with high metastatic potential and high morbidity and mortality
[3]. The role of molecular mechanisms involved in the development and progression of
prostate cancer is essential for its treatment and the prevention of CRPC.
The nuclear hormone receptor (NHR) superfamily is composed of eukaryotic
transcriptional factors that enable the regulation of gene expression through the response to
specific lipophilic ligands [4, 5]. As shown in Figure 1-1A, the members of the NHR
superfamily are composed of six conserved regions, designated A-F, which make up a
common functional domain structure that includes: (A/B) a variable N-terminal domain, a
well conserved (C) DNA-binding domain (DBD), (D) a hinge region, and a (E) ligandbinding domain (LBD) within a (F) C-terminal domain [6]. The N-terminal domain is often
important for transcription transactivation and harbors the ligand-independent activation
function 1 (AF-1) [7, 8]. The DBD, containing two cysteine rich zinc fingers, is crucial for
recognition of DNA specific sequences within the promoter region of a gene known as
hormone response elements (HREs) [7, 8]. The hinge region is thought to allow flexibility
16

for the NHR, therefore allowing proper DNA binding and dimerization [9]. Finally, the
LBD, aside from the binding of ligand function, mediates homo-dimerization and heterodimerization, binds to co-activator and co-repressor proteins, and harbors a liganddependent activation function 2 (AF-2). Ligands include both steroid hormones like
androgens and estrogens, and nonsteroidal hormones such as thyroid hormones, retinoic
acid, T3, and vitamin D. Hence, NHRs can be subcategorized as steroid hormone receptors,
non-steroid hormone receptors, and orphan nuclear receptors (ONRs) when ligands have
not been identified [10].
The actions of NHRs depend on several endogenous mechanisms: ligand binding,
posttranslational modification of amino acid residues, protein dimerization, nuclear
transfer, protein-protein interactions with activators or repressors, and cooperative binding
with other transcription factors (TFs) to DNA [4, 9, 11]. The widespread mechanism of
action model for NHRs is often represented by an inactive cytoplasmic receptor, which
upon ligand binding, translocates to the nucleus and activates gene expression. While the
model is valid for most steroid hormones, some NHRs are constitutively nuclear, and can
be bound to DNA in the absence of ligands, can act as repressors of gene expression, or can
regulate gene expression via interactions with TFs [12].
There have been 48 different NHRs identified in humans. Originally, 36 receptors
were classified as ONRs because of the apparent absence of ligands for transcriptional
function and their undefined exact function. Because of recent research efforts, 21 of these
ONRs became documented as “adopted” due to the discovery of their natural or synthetic
ligand [11].
DAX-1 is a peculiar orphan receptor encoded by the NR0B1 gene with important
roles in development, physiology, and disease. Given its involvement in two different
17

human diseases, the protein’s name stands for Dosage sensitive sex reversal (DSS), Adrenal
hypoplasia congenita (AHC) critical region on chromosome X, gene 1. DAX-1 was
classified among nuclear receptors due to the C-terminal domain homology of the DAX-1
gene product to nuclear receptor LBDs [13]. The DAX-1 gene is localized in region p21 of
the X chromosome, and includes two exons of 1168 and 254 base pairs separated by a 3.4kb intron. DAX-1 is predominantly expressed in developing adrenals, gonads, pituitary
gland, and hypothalamus [14]. The DAX-1 protein consists of 470 amino acid residues and
lacks several conserved functional domains in contrast to the majority of NHRs as shown in
Figure 1-1B. These domains include the modulatory domain harboring an AF-1
transactivation unit, a classical DBD, and a hinge region. Instead of these domains, the
DAX-1 exon 1 encodes three full-length Alanine/ Glycine-rich repeats of 65-67 amino acid
residues and a single shortened repeat [15]. These repeats harbor LXXLL-like motifs,
usually encountered in nuclear receptor coactivators or corepressors. The C-terminal
domain of DAX-1 consists of 12 a-helices, a repressor domain, and a domain similar to the
ligand-inducible domain, but its natural ligand has not been identified. An additional
feature of the DAX-1 protein is that its LBD domain contains a long insert of
approximately 26 amino acid residues [15].
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Figure 1-1. Structural organization of nuclear hormone receptors and DAX-1. A. The
general structure of nuclear hormone receptors depicting an N-terminal domain (A/B), a
DNA binding domain or DBD (C), a hinge region (D), a ligand binding domain or LBD
(E), and a C-terminal domain (F). B. The protein structure of DAX-1 with 470 amino acid
residues contains 3 alanine/glycine rich repeats and 3 LXXLL-like motifs on the N-terminal
end, a 1/2 alanine/glycine rich repeat at the beginning of the C-terminal domain, and a
ΦΦXEΦΦ motif at the end of the C-terminal domain.
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Initial experiments that led to the discovery of DAX-1 consisted of mutations that
inactivated the protein, causing AHC, or an increase in DAX-1 dosage, leading to DSS.
Since its discovery, numerous studies have highlighted the role DAX-1 plays in
development, physiology, and disease. Studies have shown that DAX-1 expression
correlates negatively with steroidogenic gene expression and that the DAX-1 gene product
also acts as a repressor of steroidogenesis in vivo [16, 17]. Because DAX-1 lacks the classic
DBD, its mechanism of action has been explained through interactions with many NRs for
the regulation of their activities. DAX-I acts as a transcriptional corepressor in the majority
of its interactions with other NRs. Examples of these interactions include SF-1, androgen
receptor (AR), progesterone receptor (PR), estrogen receptor (ER), Nur77, hepatocyte
nuclear factor 4a (HNF4a), liver X receptor Xa (LXRa), farnesoid X receptor (FXR) , and
constitutive androstane receptor a (CARa) [13, 15]. The common mechanism of DAX-1
transcriptional repression is through binding with the AF-1 domain of a NR via the LXXLL
motifs and recruiting other corepressor proteins, competing with coactivators for target
gene binding [18].
In view of the role DAX-1 plays in transcriptional regulation, various studies have
been completed to explain the functions DAX-1 has in several types of diseases, including
cancer. Initial studies analyzing DAX-1 expression in the context of cancer concerned
adrenocortical neoplasms. Studies suggested that DAX-1 expression might influence the
order of steroids produced by tumors, hence putatively linking the role of DAX-1 with cell
proliferation and tumor formation [19]. More recent research has reported and correlated
DAX-1 expression with clinical parameters in different types of human neoplasms
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including: pituitary adenomas, ovarian carcinomas, breast cancer, endometrial carcinoma,
prostate cancer, lung cancer, Ewing Tumors, and other soft tissue tumors. In the context of
prostate cancer, DAX-1 immunoreactivity was shown to be inversely and significantly
correlated with Gleason score, a grading system used to evaluate malignancy in this type of
cancer [20]. Comparably, DAX-1 immunoreactivity has been shown in endometrial
carcinoma and breast cancer, correlating inversely with histological grade and with nodal
status respectively [20, 21]. In contrast, higher DAX-1 expression in lung cancer patients
has been correlated with higher risk of disease recurrence and a higher metastatic rate [22].
Underlying the different roles DAX-1 has with cell proliferation and tumor formation in
human neoplasms is the interaction of DAX-1 with other NHRs. In the context of breast
cancer, DAX-1 expression was reported to be directly correlated with androgen receptor,
while in the context of prostate cancer there was no significant correlation with the status of
AR, ER-b or PR in patient samples [20, 21]. However, DAX-1 has been shown to suppress
agonist-dependent activity of AR in human prostate carcinoma cell lines [23]. Moreover,
DAX-1 has been shown to down-regulate AR in monkey kidney cells [24]. Nonetheless,
the relation between AR activation and DAX-1 expression has not been elucidated in the
context of prostate cancer.
Androgens, acting through AR are necessary for prostate development and normal
prostate function. However, AR remains important in prostate cancer development and
progression. ADT is the primary course of treatment for patients diagnosed with prostate
cancer. Clinical and animal prostate cancer studies suggest that many prostate neoplasms
are resistant to ADT-induced apoptosis at the time of treatment and that the observed
therapeutic gain may be the result of a decrease in the proliferation rate of the tumor cells
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[25]. However, studies have shown an increased cell growth in androgen deprived cells
under overexpression of the anti-apoptotic gene bcl-2 and enhanced tumor formation in
castrated male mice [26]. Inhibition of the anti-apoptotic gene bcl-2 through AR-mediated
androgen action was proposed as a mechanism for up-regulated bcl-2 expression upon
androgen deprivation [27]. In the context of cell line models, cell growth has been shown to
be inhibited at high concentrations of dehydrotestosterone (DHT) in androgen-dependent
prostate cancer cells [28]. In addition, DHT has been shown to potentiate the apoptotic
effect of a protein kinase C activator through AR in androgen-dependent prostate cancer
cells [29]. Similarly, transfection of AR into an AR-negative prostate cancer cell line was
shown to generate sublines that undergo growth arrest or apoptosis in the presence of
androgens [30]. However, studies have revealed that treatment of patients with castration
resistant prostate cancer metastases with doses of androgen are deleterious in a vast
majority of patients [31]. Although there are discrepancies in the data shown by clinical,
animal, and cell culture research, androgenic therapy could prove not to be the most
beneficial course of treatment for many prostate cancer patients. On the other hand,
sporadic androgen ablation could prove beneficial for preventing or delaying the
development of hormone-refractory prostate tumors.
The interaction between AR with coactivators and corepressors, such as DAX-1, in
the context of prostate cancer could explain the underlying mechanism behind the
development of a hormone refractory status after ADT and serve as a possible answer for
poor patient prognosis in CRPC. There is evidence for the role of coactivators such as
SRC-1, a member of the p160 coactivator family, being overexpressed in androgendependent PCa and that in clinical analysis SCR-1 correlated with tumor aggressiveness
and prostate growth in animal studies[32-34]. Alternatively, Alien and DAX-1 have been
22

shown to act as corepressors of AR, inhibiting PCa cell growth[23, 35]. Thus, studies
concerning the effect of AR activation in regulating specific genes that alter coactivators
and corepressors expression with diverse functions concerning the progression of prostate
cancer are crucial. While it has been shown that DAX-1 acts a corepressor of AR, the
effects of AR in the regulation of DAX-1 remain to be uncovered in the context of prostate
cancer. Because of the effect aromatase has in converting testosterone to estradiol and
acting through the estrogen receptor (ER), specific AR activation regulation of downstream
genes is essential for discerning its distinct role in the progression of prostate cancer.
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Chapter 2
DAX-1 expression in prostate cancer cells and up-regulation in AR positive cell
lines
Introduction
The progression of PCa has been greatly attributed to androgens acting on the
androgen receptor [25]. As previously mentioned, the main course of treatment for PCa is
ADT in order to reduce or stop male androgens, thereby inhibiting the activation of AR.
While effective initially, tumors become resistant to androgen deprivation and recur as the
more aggressive state of CRPC. Because the prevention of CRPC is crucial, research
involving the underlying mechanisms by which prostate cancer progresses is necessary.
These include analyses on the effects of ADT in the regulation of potentially beneficial
transcription factors that act as repressors of AR, such as DAX-1. DAX-1 was shown to
inversely correlate to Gleason scores in prostate cancer samples, possibly indicating a
beneficial marker for prostate cancer prognosis [20]. Previous studies have shown that
activation of the AR in hormone dependent breast cancer cells leads to up-regulation of
DAX-1 expression. However, whether this is true for other types of cancers such as prostate
cancer remains unclear [36]. The direct regulation of AR over DAX-1 expression in
prostate cancer cells could provide insights into the disadvantages of ADT in certain
patients and provide better therapeutics for patients with different DAX-1 or other
beneficial markers status.
The research analyzed throughout this chapter aims to uncover the link between AR
activation and DAX-1 regulation in the context of prostate cancer cells. In order to do this,
cell line models were used as means to study and analyze the effects of AR activation and
DAX-1 expression. Three human prostate cancer cell line models were used for these
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experiments, all representing different phenotypic variables for AR and DAX-1 expression
status. The human cell line LnCap (epithelial prostatic carcinoma cells) was used as an
AR/DAX-1 positive cell line, the human cell line PC3 (epithelial prostatic adenocarcinoma
cells) was used as an AR/DAX-1 negative cell line, and the human cell line DU145
(epithelial prostatic carcinoma cells) was used as an AR negative/ DAX-1 positive cell line
[37]. The AR/DAX-1 status and the tumorigenicity of these cell lines are summarized on
Table 2-1.

Table 2-1. AR/DAX -1 status in prostatic cancer cell lines.
Cell line

AR status

DAX-1 status

Tumorigenicity

LnCap

Positive

Positive

Low

PC3

Negative*

Negative

High

DU145

Negative*

Positive

Moderate

*Recent studies have shown that although commonly known as Androgen independent cell
lines (AR negative) these cells express minimal amounts of AR [38].

During normal steroidogenesis, testosterone is aromatized to estradiol (E2) by the
enzyme p450-aromatase. In turn, E2 is able to activate the Estrogen Receptor (ER) thereby
activating diverse signaling pathways [39]. Some studies have shown that ER creates
accelerated growth in prostate cancer cells which can be inhibited by the use of
antiestrogens like ICI [40]. In light of the discovery of ER isoforms, research has focused
on the diverse roles these have in the prognosis of prostate cancer. The two isoforms of ER
b2 and ER b5 were shown to be associated with aggressive cell migration and invasion and
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poor patient prognosis in prostate cancer [41]. In addition, other studies have suggested that
different isoforms of ER can also have opposing roles when it comes to the aggressiveness
of prostate cancer cell growth and metastatic behavior [42]. Because of the potential
deleterious role of ER in the progression of prostate cancer, the study of the independent
role of AR is crucial. The aggressive behavior of prostate cancer cells, and the metastatic
and proliferative properties of prostate cancer tumor growth shown in animal and clinical
data can then by accounted for by the effects on activation of other NHRs such as ER and
PR. In order to analyze the sole role of AR, the non-aromatizable androgen Metribolone
(Mb) was used to treat prostate cancer cells and analyze the effects on the regulation of
DAX-1. As shown in Figure 2-1, we expected to see an up-regulation of DAX-1 expression
in the DAX-1 positive cell lines after treatments with Mb.
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DAXJ1
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AR
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Figure 2-1. Putative regulation of DAX-1 expression by AR. Mb does not get
aromatized to estradiol by the enzyme p450-aromatase. Mb activates AR, translocating the
protein to the nucleus where it binds the promoter region of DAX-1, up-regulating its
transcription.
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In order to analyze the binding of AR to the promoter region of DAX-1, chromatinimmunoprecipitation (ChIP) was performed. The association between proteins and DNA is
crucial for many cellular functions including transcription. Once the link between AR
receptor activation and up-regulation of DAX-1 was established, we explored the role that
sole AR activation plays in the regulation of proliferation, apoptosis, and metastasis in
prostate cancer cells. We were also able to analyze the specific changes that AR activation
and DAX-1 expression cause on distinct markers that regulate proliferation, apoptosis, and
metastasis in these cells. Moreover, we analyzed which of these changes can be attributed
exclusively to DAX-1 by utilizing two methods: Crispr/Cas9 and transient transfection.
Finally, we analyzed the effects AR activation and DAX-1 expression have on the rates of
proliferation, apoptosis, and metastasis. These results will provide new insights and
awareness of the important roles transcriptional repressors have on influencing the
progression of PCa and how this might affect current therapeutics like ADT.
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Materials and Methods
Reagents
Metribolone (Mb), also known as Methyltrienolone or R1881 >99%, was purchased
from Tszchem - BIOTANG Inc. (Lexington, MA, USA). Cells were treated at final
concentrations of 1µM, 100nM, 10nM, 1nM, and 1pM, or 1% Ethanol (ETOH) for
untreated. For every experiment, cells were plated and starved in 1% FBS media for 24
hours prior to treatments.

Cell culture
All cells were obtained from the American Type Culture Collection (ATCC). All
cell lines were routinely passaged, cultured, and maintained at 37° C in a humidified 5%
CO2 tissue culture incubator. Both LnCap and PC3 human prostate cancer cells were
cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium with phenol red and
modified with L-Glutamine. Media was supplemented with 10% charcoal-stripped Fetal
Bovine Serum (FBS) (ATCC, Manassas, VA), 1% Penicillin/Streptomycin (Invitrogen,
Carlsbad, CA), 1% HEPES (Mediatech, Inc., Manassas, VA), 1% Sodium Pyruvate (Life
Technologies, Carlsbad, CA), 0.9% Glucose (Mediatech, Inc., Manassas, VA) and 0.2%
Sodium Bicarbonate (Mediatech, Inc., Manassas, VA). DU145 cells were cultured in
Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) Medium without
HEPES or Phenol Red and modified with L-Glutamine. Media was supplemented with 10%
charcoal-stripped Fetal Bovine Serum (ATCC, Manassas, VA) and 1%
Penicillin/Streptomycin (Invitrogen, Carlsbad, CA). DU145 cells were also cultured in
RPMI 1640 Medium modified with GlutaMAX, phenol red and HEPES. Media was
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supplemented with 10% charcoal-stripped FBS (ATCC, Manassas, VA) and 1%
Penicillin/Streptomycin (Invitrogen, Carlsbad, CA).
To passage and maintain cells, cells were first washed with phosphate buffered
saline (PBS), treated with 0.05% Trypsin-EDTA (Technologies, Carlsbad, CA) and
incubated at 37°C until released from flask. Cells were re-suspended and passaged at a 1:4
to 1:10 ratio depending on cell density.

RNA extraction and cDNA synthesis
Total RNA was isolated following 24-36 hour treatments using the RNeasy Mini
Kit (Qiagen, Valencia, CA) as per the manufacturer's instruction, with the optional RNaseFree DNAse (Qiagen) step added to remove genomic DNA contamination. RNA was
measured for concentration and purity using the NanoDrop 1000 Spectrophotometer
(Thermo Scientific, Wilmington, DE). The QuantiTect Reverse Transcription Kit (Qiagen)
was used to synthesize cDNA from the isolated RNA according to manufacturer's
instructions.

PCR
cDNA synthetized from extracted mRNA was used as a template for standard PCR.
Samples were prepared using 10µL of 2X GoGreen (Promega, Madison, WI), Dream Taq
Green PCR 2X Master Mix (Thermo Scientific, Wilmington, DE) or Taq 2X Master Mix
(New England BioLabs, Ipswich, MA), 0.5µL of 10µM forward and reverse primers (see
Table 2-4), 8.5µL of dH2O, and 1µL of cDNA. PCR was performed using MJ Mini
Personal ThermoCycler (BioRad, Hercules, CA) using the protocol below with varying
annealing temperatures.
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Table 2-2. Thermocycler conditions for standard PCR.
Step
Initial Denaturation
30 Cycles:
Denaturation
Annealing
Elongation
Final Extension
Hold

Temperature
95ºC

Time
5 minutes

95ºC
48-65ºC
72ºC
72ºC
4ºC

30 seconds
30 seconds
45 seconds
4 minutes
∞

Following PCR, samples were electrophoresed through a 2% 1X TAE agarose gel
(Thermo Scientific, Wilmington, DE) containing ethidium bromide (EtBr)(Biorad,
Hercules, CA) at 0.5 µg/mL final concentration, usually about 2µl per 100mL gel. PCR
products were visualized under ultraviolet light exposure using the BioRad GelDoc System
(BioRad, Hercules, CA). Images are representative of five independent experiments.
Quantitative PCR (qPCR)
cDNA synthetized from extracted mRNA was used as a template for qPCR. qPCR
reactions were performed in triplicate using the BioRad CFX96 Real-Time PCR system
(BioRad, Hercules, CA) using the protocol below with varying initial denaturation time and
annealing temperatures. qPCR reactions were prepared using 10µL of SYBR Green Master
Mix (Life Technologies, Carlsbad, CA) or QuantiTect SYBR Green PCR kit (Qiagen,
Valencia, CA), 0.5µL of 10µM forward and reverse primers (Table 2-4), 7.5µL of dH2O,
and 2µL of cDNA. GAPDH housekeeping gene was used as control and experimental
genes were compared to GAPDH as a baseline. Fold-change values were calculated by
comparing untreated and treated samples following the delta-delta Ct method. Error bars on
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qPCR results represent standard deviation of the mean. Images are representative of five
independent experiments.

Table 2-3. Thermocycler conditions for two-step amplification qPCR.
Step
Initial Denaturation
45 Cycles:
Denaturation
Annealing
+ Plate read
Hold

Temperature
95ºC

Time
5-15 minutes

95ºC
50-65ºC

15 seconds
30 seconds

4ºC

∞

Table 2-4. List of Primers used for standard PCR and two-step amplification qPCR
Gene
Name
Housekeeping
gene

GAPDH
AR

Targets
DAX-1

Forward Primer 5’-3’

Reverse Primer 5’-3’

CCATCACCATCTTCCA
GGAGCG
CCTGGCTTCCGCAACT
TACAC
GGGTAAAGAGGCGCT
ACCAG

AGAGATGATGACCCTT
TTGGC
GGACTTGTGCATGCGG
TACTCA
GCTTGATTTGTGCTCG
TGGG

Annealing
Temperature
58ºC
60ºC
56ºC

Protein Isolation
Whole cell protein lysate was collected following 48-hour treatments using a lysis
buffer mix composed of Mammalian Protein Extraction Reagent (M-PER) (Thermo Fisher
Scientific, Rockford, IL) with Halt Protease Inhibitor (Thermo Fisher Scientific, Rockford,
IL) added at a concentration of 1:100. Cells were washed with 1X PBS once for 3 minutes
at RT. Lysis buffer mix was added to cells and incubated on ice for 15 minutes. Lysate was
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centrifuged at 12,000 RPM for 10 minutes to pellet insoluble material and the supernatant
was transferred to a new tube and stored at -20°C for future analysis.
Western Blot
Western blots (WB) were performed using the Xcell II Blot Module (Invitrogen,
Carlsbad, CA) according to the NuPAGE Novex Bis-Tris Protocol (Invitrogen, Carlsbad,
CA) using 4X NuPAGE LDS sample loading buffer and 10X NuPAGE sample reducing
agent. Samples were normalized using the Coomassie Plus Bradford Protein Assay
(Thermo Fisher Scientific, Rockford, IL) and combined with sample loading buffer and
reducing-agent to a final volume of 25µL. Samples electrophoresed through gradient 412% Bis-Tris SDS-PAGE gels for 45 minutes at 200V on the Xcell II Blot Module.
Proteins were transferred from gel to PVDF membrane according to manufacturer’s
protocol using Xcell II Blot Module with blot apparatus. Transfer blots were run at 250V
for 1.5 hours. Membranes were blocked in 5% Blotto made in 1X TrisBuffered Saline with
Tween 20 (TBST) for 1 hour with rocking at 150 RPM at RT and incubated overnight at 4°
C with primary antibody (Table 2-5) made in 5% Blotto at 1:1000 dilution with rocking at
150 RPM. Membranes were washed with 1X TBST for 10 minutes three times before
secondary antibody application. Appropriate secondary antibody, either rabbit or mouse
(BD Biosciences, San Jose, CA), was prepared in 5% Blotto made with TBST at 1:1000
dilution. Membranes were incubated in secondary antibody for one hour at room
temperature with rocking at 150 RPM, and washed with TBST for 10 minutes three times
prior to developing. Western blots were developed using the Clarity Western ECL
Substrate Kit (BioRad, Hercules, CA) and analyzed using the BioRad GelDoc System
(BioRad, Hercules, CA). Images are representative of three independent experiments.
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Table 2-5. Antibodies used for Western Blot
Protein
GAPDH
DAX-1
AR

Species
Rabbit (polyclonal)
Mouse (monoclonal)
Rabbit (polyclonal)

Company
Cell Signaling, Danvers, MA
Active Motif, Carlsbad, CA
GeneTex, Irvine, CA

Immunofluorescence (IF)
Cells were plated in wells with sterilized 22x22mm VWR micro cover glass (VWR,
Radnor, PA) that were previously incubated with FBS. After a 24 hour treatment, cells
were washed 3X with PBS for 5 minutes and fixed in a 3.7% paraformaldehyde solution at
37ºC. After paraformaldehyde fixation, cells were washed 3X with PBS for 5 minutes and
fixed in an ice-cold methanol: acetone (1:1 ratio) solution and incubated at room
temperature for 10 minutes. Following methanol: acetone fixation, cells were washed 3X
with PBS for 5 minutes and permeabilized in a 0.25% TRITON 100 solution for 20 minutes
at room temperature. Following permeabilization, cells were washed 3X with PBS for 5
minutes and blocked in 1% BSA in PBS blocking buffer for 30 minutes at 37ºC to
minimize non-specific adsorption of the antibodies to the coverslip. Cells were incubated in
primary antibodies AR and DAX-1 (Table 2-5) made in blocking buffer at 1:250 dilution
for one hour at room temperature. Following primary antibody incubation, cells were
washed 3X with PBS for 5 minutes and incubated in secondary antibody Anti-rabbit-Alexa
488 and anti-mouse-Alexa 546 made in blocking buffer at 1:200 dilution for one hour at
room temperature. Cells were washed 3X with PBS for 5 minutes and the cover glass was
inverted onto a pre-cleaned 25x75mm, 1mm thick Gold Seal Rite-on micro slides (Becton
Dickinson Labware, Franklin Lakes, NJ) containing 20µL of DAPI (Life Technologies,
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Carlsbad, CA). Slides were allowed to dry overnight. Slides were viewed using a Zeiss A1
AxioObserver fluorescence microscope (Carl Zeiss Microscopy, LLC, Thornwood, NY)
and image acquisition and analysis was performed using AxioVision software. Images are
representative of three independent experiments.

Chromatin-Immunoprecipitation (ChIP)
There are two types of ChIP, differing in the preparation of the chromatin at the
beginning of the experiment. In these experiments, cross-linked ChIP (XChIP) was utilized,
in which proteins get cross-linked to the DNA they are associated with at the time of
collection or posterior to treatments. XChIP is mainly used for mapping the DNA target of
transcription factors and uses the reversible cross-linking agent formaldehyde. The crosslinked chromatin is sheared by sonication and by nuclease digestion to provide fragments
of 400-500bp. Cell debris is cleared by sedimentation and cross-linked protein-DNA
complexes are selectively immunoprecipitated using specific primary antibodies to the
protein of interest, in this case AR. A secondary antibody is commonly coupled with a
magnetic bead and is used to immunoprecipitate the primary antibody forming an
immunoprecipitated complex formed by magnetic bead-antibody-antibody-protein-target
DNA. The immunoprecipitated complex is then collected and washed to remove nonspecifically bound chromatin. The protein-DNA cross-link is reversed and proteins are
removed by digestion with proteinase K. The DNA associated is then purified and
identified using polymerase chain reaction (PCR) and quantitative PCR (qPCR) as shown
in Figure2-2.
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Figure 2-2. X-ChIP workflow. Untreated and treated cells with Mb were exposed to
formaldehyde to cross-link DNA to protein. Cells were lysed and chromatin was sheared
using sonication and digested with micrococcal nuclease to generate 400-500bp fragments.
Antibodies for the positive control Histone H3, the negative control IgG, AR, and RNA
polymerase (RNAP) were added, and the samples were immunoprecipitated to isolate the
protein of interest. Crosslinking was reversed and DNA was purified and analyzed via PCR
and qPCR analysis.
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Untreated and Mb treated LnCap cells were collected for ChIP using the
SimpleChIP Enzymatic Chromatin IP Kit (Magnetic Beads) (Cell Signaling, Danvers,
MA) according to manufacturer’s protocol. In order to crosslink protein to DNA, cells were
fixed in 1% formaldehyde and incubated for 10 minutes at room temperature. To quench
fixation, glycine was added to cells and incubated for 5 minutes at room temperature.
Media was removed and cells were washed twice with ice-cold PBS. An ice-cold solution
of 1X PBS and Protease Inhibitor Cocktail (PIC) was added and cells were scraped into the
cold buffer. Cells were centrifuged at 1,500 rpm for 5 minutes at 4ºC. Supernatant was
removed and cells were re-suspended in 1mL ice-cold Dithiothreitol (DTT), PIC and buffer
mix per immunoprecipitation (IP) and incubated for 10 minutes on ice, with inversion every
3 minutes. Nuclei were pelleted by centrifugation at 3,000 rpm for 5 minutes at 4ºC.
Supernatant was removed and the pellets were suspended in an ice-cold DTT buffer
solution. Centrifugation was repeated, supernatant was removed, and pellets were resuspended in a new DTT buffer solution. Micrococcal Nuclease was added and incubated
for 20 minutes at 37ºC with frequent mixing to digest DNA to length of approximately 150900bp. Samples were mixed by inversion every 4 minutes. The amount of Micrococcal
Nuclease required to digest DNA to the optimal length was determined for LnCap cell
lines. Digestion was stopped by adding EDTA and placing tube on ice. Nuclei were
pelleted by centrifugation at 13,000 rpm for 1 minute at 4ºC and supernatant was removed.
The nuclear pellet was re-suspended in a PIC and ChIP buffer mix and incubated on ice for
10 minutes. Cells were sonicated using the Misonix S-4000 Ultrasonic Liquid Processor
(Misonix, Inc, Farmingdale, NY) at an amplitude of 75 for three pulses of 30 seconds with
a 40 second pause between pulses on ice to break nuclear membrane. Lysates were clarified
by centrifugation at 10,000 rpm for 10 minutes at 4ºC. The supernatants were transferred to
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new tubes and a standard immunoprecipitation protocol for specific antibodies was applied.
Antibodies for the protein targets Histone H3, IgG, AR and RNAP were used, summarized
in Table 2-6. Primers used to analyze the promoter region of DAX-1 and a downstream
region of transcription start site (negative control) were derived from previous known AR
binding sites [36]. The sense and anti-sense sequences for primers used to target the DAX-1
gene are summarized in Table 2-7. The locations of the primer targets within the DAX-1
gene are visible in Figure2-3.

Table 2-6 Antibodies used for ChIP assay.
Protein Target

Host Organism

Cat. No, Company

Histone H3

Rabbit (polyclonal)

#4620, Cell Signaling, Danvers, MA

Normal Rabbit IgG

Rabbit (polyclonal)

#2729, Cell Signaling, Danvers, MA

DAX-1

Mouse (monoclonal)

#39983, Active Motif, Carlsbad, CA

RNAP

Rabbit (polyclonal)

#AB5131, Abcam, Cambridge, MA
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Table 2-7. Sense and anti-sense sequences for oligonucleotides to target DAX-1 gene
for ChIP.
Guide

Primer sequence

Target

DAX-1-1

5’-AATGCAGGAACAGAAAACCAAATA-3’ (forward)

Promoter

Color
code
Yellow

Promoter

Green

Downstream
from
transcription
start site

Pink

5’-GGCAGCGAGCAGGATGTAAAAGTG-3’ (reverse)
DAX-1-2

5’-CAGCATCCAGGACATAGTGG-3’ (forward)
5’-GCTGGAAATGGAAGAACAGC-3’ (reverse)

DAX-1-C

5’-TGCTGCCAGCTCATAGTCAC-3’ (forward)
5’- GCAGCTGTCCTCAGAAAAGG-3’ (reverse)

Statistical Analysis
Statistical significance was calculated using the two-tailed t-test formula built
into Microsoft Excel. Data was found to be statistically significant if p< 0.05.
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---------------------------------------------------------------------3721 tgtcttcaca gctgtgtggc aagtgaagac taatggatcc aggcttcctg atgcttctat
3781 ttatcattat tcacttagga agggtgggaa aagaaatact aattacacac ttaccaatgg
3841 aatactttta caaggatcaa aatttctcac tgcggccatg aaaaagaatg agagctggcg
3901 gccatcatgc ttagcaaagt aatgcaggaa cagaaaacca aatatcacat gttctcactt
3961 gcaagtggga gctaaataaa gagatcacct ggacactagg aggggaacaa cagacactgg
4021 aacctacttg aaggtggagg gtgggaagag ggagagaatg agaaaaaata cctattggat
4081 actattacct gggtgatgaa ataatctgta caccaaaccc ccacgacaag caattcactt
4141 atataacaaa cccgcacatg tactcctgaa cctaaaagtt aaaagaaaaa aaaatatata
4201 ctaaaatgaa aacaattctc actgtaacaa tattatcccc tcgtaattat tatattccta
4261 agttttaggc acttttacat cctgctcgct gcccccagct ctcttaacac agcatccagg
4321 acatagtggg cgcttataaa tactgatggc attaaactga gcgcttatga tagcatattt
4381 agagcagtgc ttttcaaacg tctaggtgca tgtgaatccc tggggacacc gttaaaatgc
4441 agattcagag ttagaaagtc tggttggagc ctgagattgg gcatttccac cgagttccca
4501 tatgatgctt gtctatgttc tgtatttttc aaggtctcag aaaatgagac ctccctatcc
4561 atatacaaat ataagtcaca caaactgtga taatttaatg aaagtttaca aagagcatag
4621 aagtagatgt ttcctctttt cccctgccct cccaataaag ggaacaaatt agatgcgagg
4681 gttcaatgga aagagttgca acagcatcca ggcgctcgct ctcctccggt cttcctgaga
4741 cagggaaagg ggtaatgaga ggaaggagga aagtgtccag gagctcccac gctgctgttc
4801 ttccatttcc agcttttaaa gagcacccgc cccttcgaac caccgaggtc atgggcgaac
4861 acaccggagc gcagcaccgc gcccccccgc acacaccgcc cgcctccgcg cccttgccca
4921 gaccgaggcg gccgacgcgc ctgcgtgcgc gctaggtata aataggtccc aggaggcagc
4981 cactgggcag aactgggcta cgggcgccgc gggccatggc gggcgagaac caccagtggc
5041 agggcagcat cctctacaac atgcttatga gcgcgaagca aacgcgcgcg gctcctgagg
5101 ctccagagac gcggctggtg gatcagtgct ggggctgttc gtgcggcgat gagcccgggg
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Figure 2-3. Primer sequence targets within DAX-1 gene. Sequences for ChIP primers
targeting two sites in the promoter region of DAX-1 highlighted in yellow (DAX-1-1) and
green (DAX-1-2), and one downstream of the transcription start site as a control
highlighted in pink (DAX-1-C). Templates for DNA polymerase are highlighted in blue.
TATA box and transcription site highlighted in red.
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Results
Regulation of DAX-1 expression in LnCap cells
The mRNA expression of DAX-1 was up-regulated in the androgen-sensitive
prostate cancer cell line LnCap after 24-hour treatment with Metribolone, as visualized by
standard PCR electrophoresed through an agarose gel (Figure 2-4 A) and quantified via
quantitative PCR analysis (Figure 2-4 B). DAX-1 expression was up-regulated
significantly in some concentrations more than others, but at any concentration, the
expression of DAX-1 was higher in Mb treated samples than in that of the untreated
sample. As demonstrated by the qPCR analysis, the expression of DAX-1 appears to be upregulated in a semi dosage-dependent manner. The expression of AR was not changed, as
can be seen by agarose gel analyses after treatments with Mb for 24-hours (Figure 2-4 A).
However, some concentrations of Mb significantly down-regulated the expression of AR
when quantified via qPCR analysis (Figure 2-4 B). The expression of GAPDH did not
change in any treatments and was used as a positive control. GAPDH was also used as a
baseline when experimental genes were compared across treatments.
LnCap cells also demonstrated an increase in DAX-1 protein expression after 48hours of Mb treatments as shown in Western Blotting (Figure 2-5). Again, the increase in
DAX-1 protein expression occurred in a semi dosage-dependent manner, as previously
observed in the expression of DAX-1 mRNA analyses via PCR and qPCR. Furthermore,
the expression of DAX-1 protein was higher in all of the Mb treated samples when
compared to that of untreated samples. In contrast, the expression of AR appears to be upregulated at low Mb concentrations and down-regulated at higher Mb concentrations, which
was not observed in mRNA analyses. The expression of GAPDH did not appear to change
in any treatments and was used as a positive control.
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Figure 2-4. Up-regulation of DAX-1 mRNA expression in the androgen-sensitive
prostate cancer cell line LnCap. A. Agarose gel electrophoresis of PCR samples
comparing AR and DAX-1 expression in untreated (1%ETOH) and Mb treated LnCap
cells. B. qPCR results showing fold-change expression of AR and DAX-1 mRNA in Mb
treated samples compared to untreated sample in Lncap cells. GAPDH was used as a
control and experimental genes were compared to GAPDH as a baseline. Fold-change
values were calculated by comparing untreated and treated samples following the D-DCt
method. Error bars on qPCR results represent standard deviation of the mean. A single
asterisk (*) represents samples that were p<0.05, a double asterisk (**) represents samples
that were p<0.005, and a triple asterisk (***) represents samples that were p<0.0005.
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Figure 2-5. Up-regulation of DAX-1 protein expression LnCap cells. Western Blot
analysis comparing AR and DAX-1 protein expression in untreated and Mb treated LnCap
cells. GAPDH was used as a positive control.
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As observed in PCR, qPCR, and Western Blot analyses, the expression of DAX-1
protein was up-regulated in a semi dosage-dependent manner when visualized under
immunofluorescence with confocal microscopy after 48-hour Mb treatments (Figure 2-6).
Interestingly, the expression of AR was downregulated in lower concentrations of Mb
treatments and upregulated at higher concentrations, contrary to what was observed in
Western Blot analysis. Both AR and DAX-1 proteins were observed to co-localize in both
the nucleus and the cytoplasm. Nuclei were stained with DAPI.
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Figure 2-6. Immunofluorescence analysis of DAX-1 protein expression up-regulation
in LnCap cells. Confocal visualization of AR and DAX-1 protein expression in untreated
and Mb treated LnCap cells showing localization of proteins both nuclear and cytoplasmic.
Nuclei were stained with DAPI. Scale bar represents 10µm.
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Regulation of DAX-1 expression in PC3 cells
Similar to the results observed in LnCap cells, 24-hour Mb treatments up-regulated
the expression of DAX-1 mRNA in PC3 cells, as visualized by standard PCR run through
an agarose gel (Figure 2-7 A) and quantified via qPCR analysis (Figure 2-7 B). The upregulation of DAX-1 expression with Mb, while lower in fold change when compared to
LnCap results, was again observed to occur in a semi dosage-dependent manner. Similarly,
the expression of DAX-1 was higher in all Mb treated samples compared to that of
untreated sample. This indicated some sensitivity of AR to Mb treatments in PC3 cells.
While these cells are globally known as androgen-insensitive, our data suggests that almost
negligible amounts of AR are present, which explains their sensitivity to androgen.
Although hard to detect, expression of AR in PC3 cells was observed by agarose gel
analysis (Figure 2-7 A), which supports the findings previously suggested by Alimirah, et
al. [38]. As seen in LnCap cells, the expression of AR did not change in any of the
treatments with Mb when visualized on the agarose gel. However, AR expression was
observed to be significantly down-regulated at low Mb concentrations as observed in
LnCap qPCR analyses (Figure 2-7 B). The expression of GAPDH did not change in any
treatments and was used as a positive control. GAPDH was also used as a baseline when
experimental genes were compared across treatments.
Western Blot analysis demonstrated an up-regulation of DAX-1 protein expression
in 48-hour Mb treated samples (Figure 2-8). All Mb treated samples showed an upregulation of DAX-1 protein expression when compared to the untreated sample. Contrary
to the AR mRNA expression observed in PCR and qPCR analyses, AR protein was not
detectable by Western Blot analyses. The expression of GAPDH did not appear to change
in any treatments and was used as a positive control.
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Figure 2-7. Up-regulation of DAX-1 mRNA expression in the androgen-insensitive
prostate cancer cell line PC3. A. Agarose gel electrophoresis of PCR samples comparing
AR and DAX-1 expression in untreated (1%ETOH) and Mb treated PC3 cells. B. qPCR
results showing fold-change expression of AR and DAX-1 mRNA in Mb treated samples
compared to untreated sample in PC3 cells. GAPDH was used as a control and
experimental genes were compared to GAPDH as a baseline. Fold-change values were
calculated by comparing untreated and treated samples following the D-DCt method. Error
bars on qPCR results represent standard deviation of the mean. A single asterisk (*)
represents samples that were p<0.05, a double asterisk (**) represents samples that were
p<0.005, and a triple asterisk (***) represents samples that were p<0.0005.
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Figure 2-8. Up-regulation of DAX-1 protein expression in PC3 cells. Western Blot
analysis comparing AR and DAX-1 protein expression in untreated and Mb treated PC3
cells. GAPDH was used as a positive control.
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Neither the expression of AR nor the expression of DAX-1 protein was visible in
confocal microscopy studies after immunofluorescence protocol (Figure 2-9). Nuclei in
PC3 cells were stained with DAPI.
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Figure 2-9. Immunofluorescence analysis of DAX-1 protein expression regulation in
PC3 cells. Confocal visualization of AR and DAX-1 protein expression in untreated and
Mb treated PC3 cells. Nuclei were stained with DAPI. Scale bar represents 10µm.
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Regulation of DAX-1 expression in DU145 cells
DAX-1 expression was not observed to change across untreated and Mb treated
samples in DU145 cells as verified by standard PCR run through an agarose gel (Figure 210 A). These cells were observed to express significant amounts of DAX-1 independent of
Mb treatments. All untreated and Mb treated samples expressed the same amounts of DAX1. While AR mRNA expression was not observed by agarose gel analysis, there was
significant up-regulation of DAX-1 expression when quantified via qPCR (Figure 2-10 B).
These results again seem to support findings by Alimirah, et al.[38]. DAX-1 was upregulated even where there was no detectable AR in DU145 cells via PCR (Figure 2-10 A),
as opposed to the traceable amounts observed in PC3 cells (Figure 2-9 A). These results
suggest a small sensitivity of DU145 cells to androgens, even when AR was not observed.
Again, the up-regulation of DAX-1 appeared to occur in a semi dosage-dependent manner
as verified by qPCR analysis (Figure 2-10 B). Only the extremely high concentration of
1µM Mb resulted in a significant change in the expression of AR as visualized by qPCR.
The expression of GAPDH did not change in any treatments and was used as a positive
control. GAPDH was also used as a baseline when experimental genes were compared
across treatments.
Similar results were observed in Western Blot protein analyses of DU145 cells
(Figure 2-11). AR protein was not observed in any of the Mb concentration treatments and
the expression of DAX-1 protein was slightly up-regulated at increasing doses of Mb.
These cells express significant amounts of DAX-1 protein independent of AR activation.
The expression of GAPDH did not appear to change in any treatments and was used as a
positive control.
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Figure 2-10. Regulation of DAX-1 mRNA expression in the androgen-insensitive
prostate cancer cell DU145. A. Agarose gel electrophoresis of PCR samples comparing
AR and DAX-1 expression in untreated (1%ETOH) and Mb treated DU145 cells. B. qPCR
results showing fold-change expression of AR and DAX-1 mRNA in Mb treated samples
compared to untreated sample in DU145 cells. GAPDH was used as a control and
experimental genes were compared to GAPDH as a baseline. Fold-change values were
calculated by comparing untreated and treated samples following the D-DCt method. Error
bars on qPCR results represent standard deviation of the mean. A single asterisk (*)
represents samples that were p<0.05, a double asterisk (**) represents samples that were
p<0.005, and a triple asterisk (***) represents samples that were p<0.0005.
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Figure 2-11. Regulation of DAX-1 protein expression in DU145 cells. Western Blot
analysis comparing AR and DAX-1 protein expression in untreated and Mb treated DU145
cells. GAPDH was used as a positive control.
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Mirroring the results from the Western Blot analyses, AR protein expression was
not visible via confocal microscopy studies following immunofluorescence protocols
(Figure 2-12). No change in the expression of DAX-1 protein was observed across either
untreated and treated samples. In addition, DAX-1 protein appeared to localize both in the
nucleus and the cytoplasm as previously observed in LnCap cells even in the apparent
absence of AR. Nuclei in DU145 cells were stained with DAPI.
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Figure 2-12. Immunofluorescence analysis of DAX-1 protein expression regulation in
DU145 cells. Confocal visualization of AR and DAX-1 protein expression in untreated and
Mb treated DU145 cells showing localization of DAX-1 protein both nuclear and
cytoplasmic. Nuclei were stained with DAPI. Scale bar represents 10µm.
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ChIP analysis of AR binding to DAX-1 promoter
Three regions targeting the DAX-1 gene were selected for ChIP analysis. Two
different DAX-1 promoter regions were targeted for AR binding and one region
downstream from the transcription start site was targeted as a control. Each region had
variable lengths ranging from about 300 to 500 base pairs (Figure 2-13). These regions
were selected from previous literature in which AR was shown to bind the DAX-1
promoter region in breast cancer cells studies [36].
In untreated samples, AR or RNAP binding was not observed in any of the regions
targeted in the promoter region or control as verified by PCR followed by agarose gel
electrophoresis (Figure 2-14 A, C, E). This indicated that AR activation by Mb treatment is
necessary for AR translocation to the nucleus and regulation of DAX-1 gene. In the case of
samples treated with Mb, AR and RNAP were observed in both targeted areas of the
promoter region of DAX-1. The highest levels of AR and RNAP were observed in samples
treated with high concentrations of Mb. In addition, the highest level of AR and RNAP
binding occurred in the region targeted by DAX-1-2 primers, a region that spans a range of
706 to 202 base pairs upstream of DAX-1 transcription start site (Figure 2-14 C). AR
binding was observed in all Mb treatments in the region targeted by DAX-1-1, a region that
spans a range of 1095 to 722 base pairs upstream of DAX-1 transcription start site (Figure
2-14 A). RNAP was observed in all samples treated with Mb in the region targeted by
DAX-1-2 and at only high Mb concentrations in the area targeted by DAX-1-1. Significant
binding of AR and RNAP in the region targeted by DAX-1-1 was only observed in samples
treated with 10nM Mb concentrations, as quantified via qPCR (Figure 2-14 B).
Interestingly, significant binding of AR and RNAP was observed in all Mb treated samples
in the area targeted by DAX-1-2, as shown by qPCR analysis (Figure 2-14 D). Finally, no
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AR or RNAP binding was observed in any of the samples on the control region targeted by
DAX-1-C, a region that spans a range of 6191 to 6637 base pairs downstream of DAX-1
transcription start site as verified by PCR followed by agarose gel electrophoresis (Figure
2-14 E) and qPCR analysis (Figure 2-14 F). The negative control normal IgG was not
observed in any immunoprecipitations, in contrast to the positive control Histone H3 which
was observed for all treatments. There was no significant fold change between Mb
treatments for these controls, as can be seen in the qPCR analyses (Figure 2-14 B, D, F).
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Figure 2-13. Targeted regions for ChIP in DAX-1 gene. Two regions (DAX-1-1 and
DAX-1-2) were targeted in the promoter region of DAX-1 upstream of the transcription
start site. A control region (DAX-1-C) was targeted downstream of the transcription start
site. All regions had individual lengths of about 300 to 500 base pairs.
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Figure 2-14. ChIP analyses of AR and RNAP binding to the DAX-1 promoter. A.
Agarose gel electrophoresis of PCR product using DAX-1-1 primers targeting the promoter
region of DAX-1 in untreated (ETOH) and Mb treated samples. B. qPCR results comparing
the different treatments in ChIP experiments using DAX-1-1 primers. C. Agarose gel
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electrophoresis of PCR product using DAX-1-2 primers targeting the promoter region of
DAX-1 in untreated and Mb treated samples. D. qPCR results comparing the different
treatments in ChIP experiments using DAX-1-2 primers. E. Agarose gel electrophoresis of
PCR product using DAX-1-C primers targeting a downstream region of DAX-1
transcription start site used as a control in untreated (ETOH) and Mb treated samples. F.
qPCR results comparing the different treatments in ChIP experiments using DAX-1-C
primers. In all experiments, IgG (negative control), Histone H3 (Positive control), DAX-1,
and RNAP antibodies were used for immunoprecipitations. Error bars on qPCR results
represent standard deviation of the mean. A single asterisk (*) represents samples that were
p<0.05, a double asterisk (**) represents samples that were p<0.005, and a triple asterisk
(***) represents samples that were p<0.0005.
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Discussion
The expression of AR and DAX-1 was analyzed in three prostate cancer cell lines,
LnCap, PC3, and DU145. The results from PCR and qPCR analyses provided evidence that
activation of AR promotes DAX-1 mRNA expression. This was shown to occur in the
androgen-sensitive prostate cancer cell line LnCap, as well as the PC3 and DU145 cells,
commonly known as androgen-insensitive PCa cells. These results support evidence found
by Alimirah, et al. [38]. DAX-1 up-regulation was most drastic in LnCap cells, in which
significant amounts of AR are found. The mild up-regulation of DAX-1 expression
observed in PC3 and DU145 cells are likely due to lower AR expression levels. We were
also able to show through Western Blot analysis that AR-activation was sufficient to induce
DAX-1 gene product formation in prostate cancer cells. Additionally, through IF studies,
we determined that in the prostate cancer cell line LnCap, DAX-1 and AR proteins colocalize in the nucleus as well as the cytoplasm and that their expression changes after
treatment with different dosages of Mb. However, whether protein-co-localization
demonstrate protein-protein interactions remains to be determined.
The amount of AR expression detected, at both mRNA and protein levels, varied
across concentrations of Mb. This could be indicative of alternative co-repressors and coactivators affecting AR-expression. It has been shown that DAX-1 can also act as a corepressor of AR in prostate cancer cells [23]. The repressive properties of DAX-1 in
prostate cancer cells could indicate a tentative negative feedback loop, in which AR downregulates its own activity. Alternatively, the variation of AR expression could also be
indicative of the importance that quantities or dosages of transcription factors, such as
DAX-1, have in the expression of other NHRs and their function. The range of DAX-1
expression obtained by treatments with different concentrations of Mb allowed for
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identification of different doses that up-regulate or down-regulate the expression of AR. In
addition, time-course studies exploring the expression of AR and DAX-1 after Mb
treatments could provide better evidence of the intricate regulation of AR and DAX-1 on
regulating their own expression.
The diverse DAX-1 expression across prostate cancer cell lines could also explain
the tumorigenic and proliferative behaviors of these cells. LnCap cells have the lowest
aggressive behavior among these cells, and this could be representative of the moderate
expression of DAX-1 and AR. In contrast, DU145 cells that express high concentrations of
DAX-1 and no AR have high tumorigenic and proliferative behavior. A similar behavior is
observed in PC3 cells that express high concentrations of AR and no DAX-1. These results
provide evidence of the existence of a DAX-1 expression threshold that governs the
tumorigenic and proliferative behavior of PCa cells. The effects of different doses of
transcription factors and their consequences in the aggressiveness of cell behavior remains
to be an open area of research.
Similar to results found in breast cancer cells, a direct regulation of transcription
exists on the DAX-1 gene after activation of AR in PCa cells [36]. However, reporter
assays are needed to examine the resulting transcriptional activity. In addition, future work
is needed to ascertain if the same mechanism occurs in other types of cancers, in particular
those driven by androgens. In these studies, RNAP was immunoprecipitated as a marker for
activated DAX-1 transcription upon AR binding. RNAP was shown to appear only in
certain concentrations of Metribolone, which indicates a threshold in the amount of AR
activation required to activate transcription of the DAX-1 gene. The detection of such a
threshold could prove beneficial for accurately determining the fate of a cell, critical for
cancer therapeutics.
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DAX-1 immunoreactivity has been shown to be inversely and significantly
correlated with Gleason score in prostate cancer samples, generating a potential beneficial
marker for patients with PCa [20]. These results provide initial data showing the putative
link between AR activation and DAX-1 expression in the context of prostate cancer.
Further analysis on the implications of DAX-1 in regulating genes involved in the
progression of prostate cancer are essential. The effects of DAX-1 on proliferation,
apoptosis, and metastasis in the context of prostate cancer cells will be addressed in
Chapter 3, Chapter 4, and Chapter 5, respectively. Results from these experiments will shed
light on the co-regulatory effects of AR and DAX-1 and their resultant consequences on
cell aggressive behavior in the context of prostate cancer.
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Chapter 3
Regulation of proliferation by AR and DAX-1 in prostate cancer cells
Introduction
Within the complexity of every cancer, certain factors propel tumor cell growth
through uncontrolled expansion and invasion. One of these factors is deregulated cell
proliferation that typically partners with apoptosis suppression and metastatic facilitators
creating optimal conditions for aggressive tumor behavior. The role of DAX-1 on
influencing the proliferation of prostate cancer cells will be explored in this chapter, its role
in influencing apoptosis will be explored in the next chapter (Chapter 4), and its role on
influencing metastasis will be explored in Chapter 5.
The androgen receptor (AR) plays a pivotal role in regulating the proliferation of
prostate cancer cells. The study of the multiple downstream targets of AR and their
involvement in regulating proliferation is crucial. There are multiple studies outlining the
effects of AR activation and the expression of multiple proliferative agents. For example,
5α-dihydrotestosterone (DHT) stimulation of AR has been shown to increase expression of
Cyclin D proteins and to enhance cell cycle progression [43]. Moreover, androgens have
been shown to mediate their mitogenic effects by increasing transforming growth factor
(TGF)- alpha and epidermal growth factor (EGF) [44]. Interestingly, treatment of PCa cells
with high concentrations of DHT has been shown to decrease cell yields in the androgensensitive prostate cancer cell line LnCap [28]. Consequently, these results could reveal a
dosage-sensitive differential role of the androgen receptor. Comparably, androgens have
also been shown to have anti-proliferative effects in the prostate cancer cell line PC3 after
re-expression of AR [45]. AR has also been shown to act as both a tumor suppressor and
proliferator in prostate cancer cell lines [46]. With dual effects in the proliferation of
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prostate cancer cells, the study of androgen-induced downstream targets is important to
better understand the role of AR in prostate cancer.
The known negative effects of AR on prostate cancer progression and the seemly
positive effects of ADT could be better understood by investigating the role of androgeninduced cellular RNA fragments, such as microRNAs, that prevent the translation of
particular proteins. The androgen responsive microRNAs, miR-21 and miR-148a, have
been shown to promote prostate cancer cell growth [47, 48]. While beyond the scope of this
study, the role of androgen-induced miRNAs could provide an explanation for the
proliferative effects of AR activation presented in several studies. The discovery of key
regulatory markers that induce the proliferation of prostate cancer cells could expose new
therapeutic targets for PCa that could prevent ADT’s detrimental effects and also prevent
the development of CRPC.
Studying the effects of AR activation and regulation of transcriptional repressors
could provide insight into the self-regulation of AR function. While ADT is the main
course of therapeutic intervention for prostate cancer, the mechanism by which CRPC
develops is poorly understood. The role of androgen-induced transcriptional repressors that
may result in the inhibition of proliferation can determine the need for alternative
therapeutic avenues for PCa and could also explain a mechanism for CRPC occurrence. In
light of the anti-proliferative actions of DAX-1 in breast cancer [36], linking the regulation
of AR to DAX-1 expression and the effects of DAX-1 on proliferation in prostate cancer
cells needs to be investigated. This could explain, at least in part, some of the antiproliferative effects of AR. The role of DAX-1 regulation of key proliferation genes in the
context of prostate cancer has not been previously explored.

65

Chapter 2 presented evidence of a link between AR activation and DAX-1
expression. This chapter exposes the effects of AR activation with the non-aromatizable
androgen Metribolone on regulating key proliferation markers. Three methods were used to
analyze the sole role of DAX-1 regulation of these key proliferative markers. First,
CRISPR/Cas 9 technology was used to knock out (KO) DAX-1 expression in the androgensensitive LnCap cell line, which endogenously expresses DAX-1 and AR. After
establishment of the DAX-1 negative cell line model, hereinafter referred to as “LCR1” for
convenience, the effects of AR activation and regulation of proliferation markers was
explored and compared to the wild type (WT) LnCap cells. Second, transient transfection
assays were used to endogenously express DAX-1 in the DAX-1 negative cell line PC3,
and the effects on the expression of the proliferation markers were again explored. Third, to
address if changes in proliferation markers resulted in a change in proliferation rates in
these cells, EdU proliferation assays were performed.

Proliferation markers
Cell proliferation is the process by which cells reproduce, growing and dividing into
two equal copies. Growth-mediated signaling pathways activate cells to enter the cell cycle,
initiating cell proliferation. Signaling pathways are altered in many forms of cancer, and
key components functioning as proto-oncogenes can be mutated to become constitutively
active in cancers and function as oncogenes [49]. In addition, many tumor suppressors
function as negative regulators of these growth factor- mediated cell signaling pathways
[50, 51]. DAX-1 has been shown to have tumor suppressor functions in the context of
breast cancer [13, 15, 36]. However, the role of DAX-1 in prostate cancer has not been
largely studied. Checkpoint signaling along the cell cycle determines whether or not a cell
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will proliferate; thus, the effects of DAX-1 in regulating key components of the cell cycle
were explored in this chapter. Cyclins are important regulators of cell proliferation in
human cancer. Cyclin D is often deregulated in cancer and has been documented as a
biomarker for disease progression [52]. Cyclin A expression correlates with tumor
aggressiveness in certain sarcomas [53]. Cyclin E expression has been correlated with
increased tumor stage and grade, and its deregulation is associated with the development of
various cancers [54-58]. Similarly, Cyclin B1 deregulation is associated with increased
proliferation, tumorigenesis, and malignant potential in multiple cancers [59-61]. The
proliferating cell nuclear antigen (PCNA) and Ki-67 markers are commonly used as
markers of proliferation in multiple cancer related studies and their expression has also
been correlated as a marker to predict patient survival [62-65].
A summary of the cell cycle is outlined in Figure 3-1. Cyclin D, Cyclin A, and
Cyclin E regulate the transition of the G1/S phase of the cell cycle, while Cyclin B
regulates the transition of the G2/M phase of the cell cycle. PCNA is highly expressed
during the S phase of the cell cycle. Two families of genes, the cip/kip (CDK interacting
protein/Kinase inhibitory protein) family and the INK4a/ARF (Inhibitor of Kinase /
Alternative Reading Frame) family are able to prevent the progression of the cell cycle and
are commonly referred to as cell cycle inhibitors. Within these families, the p21, p27 and
p57 genes (cip/kip family members), the p16 gene (INK4a/ARF family member), and the
p53 regulatory protein are able to halt the cell cycle and function as tumor suppressors [66].
In view of the impact of cell cycle arrest on apoptosis, the effect of DAX-1 and AR
activation on regulating cell cycle inhibitors will be explored in Chapter 4, and these cell
cycle inhibitors will be analyzed as both pro-apoptotic and anti-apoptotic markers.
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Figure 3-1. The cell cycle and key regulators of proliferation. Progression through the
cell cycle involves passage through diverse checkpoints constituted by cyclin/cyclindependent kinase (CDK) complexes. Cyclins are the major regulators of the transitions
through each phase of the cell cycle. Cyclin D, cyclin A, and Cyclin E regulate the
transition of the G1/S phase of the cell cycle, while Cyclin B regulates the transition of the
G2/M phase of the cell cycle. PCNA is highly expressed during the S phase of the cell
cycle. The cell cycle inhibitors P16, P21, P27, P57, and P53 members of the cip/kip family
and the INK4a/ARF family, prevent the progression of the cell cycle.
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Studies investigating the roles of different cyclins on prostate cancer prognosis have
shown distinct results. Cyclin D1 is highly expressed in several prostate cancer cell lines,
but is not detected in normal human prostate cells [67]. Additionally, Cyclin D1
overexpression has been associated with metastatic prostate cancer to bone disease and high
proliferative index [68]. Cyclin A and D expression have also been shown to relate to
malignant features in prostate cancer including expression of Ki67, Bcl-2, histological
differentiation, and mitotic index [69]. However, Cyclin D has been demonstrated to be an
AR corepressor in tumor-derived AR alleles and polymorphisms, creating plausible
therapies for prostate cancer [70]. Down-regulation of Cyclin B up-regulates the cell cycle
inhibitor p21 and induces apoptosis in prostate cancer cells [71]. The role of nonaromatizable androgens activating AR and regulating proliferation markers, as well as the
individual role of DAX-1, will provide a better understanding of the complexity of cancer
progression and the role of transcriptional repressors on regulating proliferation. As shown
in Figure 3-2, we expect that DAX-1 will act as a transcriptional repressor, down-regulating
the expression of proliferation markers.
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Figure 3-2. Putative regulation of proliferation markers by DAX-1 in prostate cancer
cells. As a transcriptional repressor, DAX-1 potentially down-regulates the expression of
proliferation markers.
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CRISPR/Cas
CRISPR/Cas is a recent technology that can be used to functionally inactivate genes
in human cell lines. Its name stands for “clustered regularly interspaced short palindromic
repeats – CRISPR associated proteins”. Along with various other applications,
CRISPR/Cas allows a permanent modification of gene expression. The revolutionary
aspects of CRISPR/Cas9 are associated with its ability to affect gene expression through
genomic editing. This provided a better, more efficient permanent mechanism for
modifying gene expression. Some other gene silencing mechanisms, including RNA
interference or RNAi (siRNA or shRNA), that target gene expression at the mRNA level
may become obsolete in the near future [72].
CRISPR/Cas 9 has many additional genomic engineering applications that allow
scientists to investigate diverse molecular processes. Examples of alternative CRISPR/Cas
9 applications include knockdown or activation of specific genes, specific insertions or
deletions, RNA editing, and epigenetic modifications, among others [73]. CRISPR/Cas has
also been used in a wide range of organisms, including yeast [74], zebrafish [75], fruit flies
[76], plants [77], mice [78], and monkeys [79]. Novel applications for CRISPR/Cas
systems arise every day, with nucleic acid detection for pathogen detection, genotyping,
and disease monitoring, being the most recent [80]. The list of applications of CRISPR/Cas
technology for genomic engineering is endless. However, in the context of this thesis,
CRISPR/Cas 9 was used to knock out the DAX-1 gene in order to analyze the role of DAX1 in regulating proliferative, apoptotic, and metastatic markers.

EdU assay
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Cell proliferation assays are used to detect changes in cell growth and are
commonly used for assessing cell health, determining genotoxicity, and evaluating anticancer treatments. Cell proliferation measurements can be done by monitoring changes in
metabolic activity, cellular division, or DNA synthesis [81]. The measurement of DNA
synthesis is the most accurate method to detect changes in cell proliferation. Analogues of
the pyrimidine deoxynucloside thymidine are often used for measuring cell proliferation
because they may be inserted into replicating DNA, effectively tagging dividing cells [82].
Archaic methods for measuring cell proliferation involved the use of radioactive
nucleosides like tritium labeled (3H)- thymidine (3H-thymidine) [83]. The 3H-thymidine
method was then replaced by antibody-based detection of the nucleoside analog bromodeoxyuridine (BrdU). BrdU requires DNA denaturation (using acid, heat, or digestion with
DNase) to expose the BrdU so that it may be detected with an anti-BrdU antibody [84-86].
While BrdU was more advantageous than tritium labeling, the need for DNA denaturation
resulted in cell and tissue disruption along with the degradation of proteins and nucleic
acids, which limited the utility of BrdU.
The revolutionary new technique EdU and “Click Chemistry” created novel
alternatives to BrdU. EdU (5-ethynyl-2’deoxyuridine) is another nucleoside analog to
thymidine that also gets incorporated into DNA during active DNA synthesis [87-89]. In
contrast to DNA denaturation used in BrdU protocols, aldehyde-based fixation and
detergent permeabilization allow the fluorescent dye-conjugated azide, like Alexa Fluor
dye, access to the alkyne group of EdU (Figure 3-3 A). Detection of EdU is based on a
“click reaction”, a copper catalyzed covalent cycloaddition reaction between a picolyl
fluorescent dye-conjugated azide and an alkyne (Figure 3-3 B) [88, 89]. Thus, EdU can be
readily detected in intact double-stranded DNA due to the small and permeable molecule
72

which readily penetrates the cell to target EdU inserted within the DNA structure during the
“click reaction” [82]. As shown in Figure 3-3 C, EdU gets incorporated into proliferating
cells only and these populations of cells can then be measured with Flow Cytometry or
immunohistochemistry (IHC).
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Figure 3-3. EdU and “click chemistry” for labeling DNA synthesis. A. EdU gets
incorporated to new DNA during active DNA synthesis, cell fixation and permeation allow
a fluorescent dye-conjugated azide to target EDU. B. The copper catalyzed “click reaction”
allowing the covalent cycloaddition between a picolyl fluorescent dye-conjugated azide and
an alkyne. C. EdU labeled cells can then be measured through Flow Cytometry.
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Materials and Methods
Reagents
Metribolone (Mb) was used for cell treatments using the same protocol described in
Chapter 2.

RNA extraction and cDNA synthesis
RNA extraction and cDNA synthesis was performed as described in Chapter 2
using the RNeasy Mini Kit (Qiagen, Valencia, CA) as per the manufacturer's instruction,
with the optional RNase-Free DNAse (Qiagen) step added to remove genomic DNA
contamination. The QuantiTect Reverse Transcription Kit (Qiagen) was used to synthesize
cDNA from the isolated RNA according to manufacturer's instructions.

PCR
cDNA synthesized from extracted mRNA was used as a template for standard PCR
and PCR reaction samples were prepared as described in Chapter 2. Primers used for
proliferation targets are summarized in Table 3-1. Following PCR, samples were
electrophoresed through a 2% 1X TAE agarose gel (Thermo Scientific, Wilmington, DE)
containing EtBr (Biorad, Hercules, CA) at 0.5 µg/mL final concentration, usually about 2µl
per 100mL gel. PCR products were visualized under ultraviolet light exposure using the
BioRad GelDoc System (BioRad, Hercules, CA). Images are representative of five
independent experiments.

Quantitative PCR (qPCR)
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cDNA synthetized from extracted mRNA was used as a template for qPCR. qPCR
reactions were performed as described in Chapter 2. Primers used for proliferation targets
are summarized in Table 3-1. GAPDH housekeeping gene was used as control, and
experimental genes were compared to GAPDH as a baseline. Fold-change values were
calculated by comparing untreated and treated samples following the ∆-∆Ct method. Error
bars on qPCR results represent standard deviation of the mean. Images are representative of
five independent experiments.

Table 3-1. List of Primers used for standard PCR and two-step amplification qPCR
Gene
Name
Housekeeping
gene
Targets

Proliferative
genes

Forward Primer 5’-3’

CCATCACCATCTTCCA
GGAGCG
CCTGGCTTCCGCAACT
AR
TACAC
GGGTAAAGAGGCGCT
DAX-1
ACCAG
CACACGGACTACAGG
Cyclin D1
GGAGT
GTCACCACATACTATG
Cyclin A
GACAT
GTTATAAGGGAGACG
Cyclin E
GGGAG
AAGAGCTTTAAACTTT
Cyclin B1
GGTCTGGG
CTTTGGGTGCGACTTG
KI67
ACG
GCCGAGATCTCAGCCA
PCNA
TATT
GAPDH

Reverse Primer 5’-3’

Annealing
Temperature

AGAGATGATGACCCTT
TTGGC
GGACTTGTGCATGCGG
TACTCA
GCTTGATTTGTGCTCG
TGGG
CACAGGAGCTGGTGTT
CCAT
AAGTTTTCCTCTCAGC
ACTGA
TGCTCTGCTTCTTACC
GCTC
CTTTGTAAGTCCTTGA
TTTACCATG
GTCGACCCCGCTCCTT
TT
ATGTACTTAGAGGTAC
AAAT

58ºC
63ºC
56ºC
53ºC
53ºC
56ºC
48ºC
54ºC
48ºC

Protein Isolation
Whole cell protein lysate was collected as described in Chapter 2 following 48-hour
treatments.
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Western Blot
Western blots were performed using the Xcell II Blot Module (Invitrogen, Carlsbad,
CA) according to the NuPAGE Novex Bis-Tris Protocol (Invitrogen, Carlsbad, CA) as
described in Chapter 2. Antibodies used for Western Blot are summarized in Table 3-2.
Images are representative of three independent experiments.
Table 3-2. Antibodies used for Western Blot
Protein
GAPDH
DAX-1
AR
Cyclin D1
Cyclin D3

Species
Rabbit (polyclonal)
Mouse (monoclonal)
Rabbit (polyclonal)
Rabbit (polyclonal)
Mouse (polyclonal)

Cyclin A

Mouse (polyclonal)

Cyclin B1
PCNA

Rabbit (polyclonal)
Mouse (polyclonal)

Company
Cell Signaling, Danvers, MA
Active Motif, Carlsbad, CA
GeneTex, Irvine, CA
GeneTex, Irvine, CA
BD Transduction Lab, San Jose,
CA
BD Transduction Lab, San Jose,
CA
GeneTex, Irvine, CA
BD Transduction Lab, San Jose,
CA

Immunofluorescence
IF analyses were performed as described in Chapter 2 using the antibodies
summarized in Table 2-5. Images were taken using the Zeiss A1 AxioObserver
fluorescence microscope (Carl Zeiss Microscopy, LLC, Thornwood, NY) and image
acquisition and analysis was performed using AxioVision software. Images are
representative of three independent experiments.

CRISPR/Cas9- mediated DAX-1 knockout in LnCaP cells
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The CRISPR/Cas system was developed from bacteria’s and archaea’s evolved
adaptive immune defense that uses short RNA to direct degradation of foreign nucleic
acids, like viral RNA and plasmids [90, 91]. As an application for genome engineering,
gene editing is carried out with a Type II CRISPR system known as CRISPR/Cas9 [92].
The type II effector system is comprised of a long pre- CRISPR repeat-spacer RNA
(crRNA), a Cas9 (CRISPR associated protein 9) protein, and a trans-activating crRNA
(tracrRNA), necessary for processing the pre-crRNA and the Cas 9 complex formation[93].
The Cas9 protein, part of the Cas (CRISPR associated protein) protein family, is an RNAguided DNA endonuclease that induces double strand breaks (DSB) in the site-directed
DNA [94, 95]. Cas9 action is guided by a specific DNA target, the crRNA, that contains
conserved repeat fragments and a variable spacer sequence complementary to the DNA
target region [96]. Moreover, the Cas9 protein is able to use a guide with a DNA target
sequence as short as 20 nucleotides in length. The crRNA, along with the tracrRNA,
referred to as a single guide RNA (sgRNA), create an RNA duplex that acts as a complete
guide for the Cas 9 protein [97].
As shown in Figure 3-4, the sgRNA allows Cas9 to position at the gene target
location with base pairing of the sgRNA to the DNA and cleave the DNA. CRISPR/Cas9 is
a multi-step process that often employs a plasmid in order to transfect the cells. The main
components of the plasmid are the crRNA and tracrRNA, known collectively as the
sgRNA, the Cas 9 protein, and a repair template. The plasmid utilized for the creation of
the DAX-1 knockout LnCap cell line “LCR1” contained a 20 nucleotide RNA sequence
specific for targeting the location of the human DAX-1 gene in genomic DNA. As shown in
Figure 3-5 A, the plasmid contained the necessary sequences for the Cas 9 endonuclease,
the inserted guide sequence, selection genes, and a GFP selection marker. Illustrated in
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Figure 3-5 B, the CRISPR/Cas 9 knock out (KO) plasmids consisted of a pool of three
plasmids, each encoding the Cas9 nuclease and a specific 20 nucleotide guide RNA
(gRNA) targeting the human DAX-1 gene, designed for maximum knockout efficiency.
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Figure 3-4. CRISPR/Cas9 knock out mechanism. A CRISPR/Cas9 plasmid contains the
sequence for the inserted guided sequence sgRNA composed by the tracrRNA and the
crRNA and the sequence for the Cas9 endonuclease. The plasmid gets transfected to the
target cells and expressed. The Cas9 complex gets activated and binds to genome target
sequence. Double-strand cleavage occurs at target DNA site and DNA gets repaired by
either non-homologous end joining (NHEJ)or homology directed repair (HDR).
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A

B

B

Figure 3-5. CRISPR/Cas9 knockout Plasmids. A. Summary of CRISPR/Cas9 knockout
plasmid provided by Santa Cruz Biotechnology. B. Summary of CRISPR/Cas 9 knockout
plasmids consisting of a pool of three plasmids for maximum knockout efficiency. Figure
provided by Santa Cruz Biotechnology.
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The double-stranded break caused by Cas9 can be repaired by either nonhomologous end joining (NHEJ) or homology-directed repair (HDR). During NHEJ, DNA
ends are ligated without a template, which introduces imprecise and variable insertions and
deletion mutations [98]. In contrast, HDR utilizes a template to repair the site of damage
and precise point mutations and insertions are introduced to the damage site [99]. In order
to prevent off-targets and recombine selected markers at specific sites in the genome, an
HDR Plasmid was co-transfected along with the CRISPR/Cas9 knock out plasmid. This
plasmid provided a specific DNA repair template for DSB and was also used to incorporate
a puromycin resistance gene for selection of cells where Cas9-induced DNA cleavage had
occurred. As shown in Figure 3-6, the HDR plasmid contained the puromycin resistance
gene flanked by two LoxP sites to allow for further processing by the Cre vector, as well as
a red fluorescent protein sequence. The HDR plasmid also consisted of a pool of three
plasmids, each containing the HDR template corresponding to the cut sites generated by the
corresponding CRISPR/Cas9 KO plasmids. Each HDR template contained two 800 base
pair homology arms designed to directly bind to the genomic DNA surrounding the
corresponding Cas9- induced DSB DNA site.
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Figure 3-6. HDR plasmid.
HDR plasmid containing the Puromycin resistance gene
flanked by two LoxP sites and a red fluorescent protein sequence. Figure provided by Santa
Cruz Biotechnology.
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The DAX-1 CRISPR/Cas9 KO Plasmid (human) (sc-402180, Santa Cruz Biotech,
Santa Cruz, CA) was used to stably disrupt DAX-1 gene expression in LnCap cells by
causing a double-strand break (DSB) in a 5’ constitutive exon within the NR0B1 (human)
gene. In addition to the DAX-1 CRISPR/Cas9 KO Plasmid (h), cells were co-transfected
with a DAX-1 HDR Plasmid (h) (sc-402180-HDR, Santa Cruz Biotech, Santa Cruz, CA) in
order to provide a DNA repair template for the DSB as well as enable the insertion of a
puromycin selection marker at the site of cleavage for selection of cells containing a
successful CRISPR/Cas9 DSB. Co-transfection of plasmids was performed according to
manufacturer’s protocol. Briefly, LnCap cells were seeded in a 6-well culture plate
containing 1.5X105 - 2.5X105 of cells in 2mL of antibiotic-free standard complete RPMI
medium 24 hours prior to transfections. Cells were allowed to grow to 70% confluency. For
each transfection, a solution “A” containing 1 or 2µg of each Plasmid DNA [DAX-1
CRISPR/Cas9 KO Plasmid (h) and DAX-1 HDR Plasmid (h)] diluted into Plasmid
Transfection Medium (sc-108062, Santa Cruz Biotech, Santa Cruz, CA), enough to bring
final volume to 150µl, was prepared. Solution “A” was mixed and allowed to stand for 5
minutes at room temperature. Additionally, a solution “B” containing 8 and 12µl of
UltraCruz® Transfection Reagent (sc-395739, Santa Cruz Biotech, Santa Cruz, CA) and
enough Plasmid Transfection Medium (Santa Cruz Biotech, Santa Cruz, CA) to bring final
volume to 150µl was prepared, mixed, and allowed to stand for 5 minutes at room
temperature. Solution “A” was added to solution “B” dropwise, immediately vortexed, and
incubated for 20 minutes at room temperature. Media was replaced with fresh antibioticfree complete RPMI medium and 300µl of Plasmid DNA/ UltraCruz® transfection reagent
complex (Solution “A” + “B”) was added to the well dropwise and mixed by gentle
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swirling. Cells were incubated for 48 hours under conditions normally used to culture the
cells. Four transfections were performed: a 1µg plasmids/ 8µl UltraCruz® transfection
reagent, 2µg plasmids/ 8µl UltraCruz® transfection reagent, 1µg plasmids/ 12µl UltraCruz®
transfection reagent, and a 2µg plasmids/ 8µl UltraCruz® transfection reagent. Successful
knockout occurred in the cells transfected with 1µg plasmids/ 8µl UltraCruz® transfection
reagent concentration. After 48-hour incubation with DAX-1 CRISPR/Cas9 KO Plasmid
(h) and DAX-1 HDR Plasmid (h), cells were selected with puromycin. Prior to puromycin
selection, the optimal concentration for LnCap cells was determined to be 9 µg/mL
experimentally. Briefly, 48-hours post-transfection, media was aspirated and replaced with
fresh medium containing puromycin at the appropriate concentration. Cells were selected
for 5 days with aspirating and replacing with fresh selective media every 2 days. Surviving
cells were collected and recovered in complete RPMI growth media. Individual colonies
were picked and grown in parallel to obtain clonal populations for further analysis.
Successful DAX-1 CRISPR/Cas 9 knockout LnCap cells, after transfection with 1µg
plasmids/ 8µl UltraCruz® transfection reagent concentration, were named “LCR1” for
convenience, and are referred as LCR1 hereinafter. Successful knock-out was verified with
PCR and qPCR for mRNA levels, and Western Blot and Immunofluorescence for protein
levels.

DAX-1 knock-in into PC3 cells using pcDNA3.1-DAX-1 construct
An expression plasmid containing the entire DAX-1 coding sequence was utilized
in order to transiently and endogenously express DAX-1 in the DAX-1 negative prostate
cancer cell line PC3. The mammalian expression vector utilized was pcDNA3.1, which is a
5.4 kb vector derived from pcDNA™3 designed for high-level stable and transient
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expressions in mammalian hosts. The pcDNA3.1 vector contains multiple distinctive
cloning sites in the forward (+) and reverse (-) orientations in order to facilitate cloning
(Figure 3-7). Additional elements include a Human cytomegalovirus (CMV) immediateearly promoter for high-level expression of the introduced gene, a bovine growth hormone
(BGH) polyadenylation signal that allows efficient transcription termination and
polyadenylation of mRNA [100], a neomycin resistance gene for selection of stable cell
lines, an ampicillin resistance gene (β-lactamase) for selection of vector in E.coli, and an
ampicillin (bla) resistance gene (β-lactamase) that allows selection of transformants in
E.coli.
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Figure 3-7. pcDNA3.1 (+/-) vector. Summary of the features of the 5.4 kb pcDNA™3.1
vector utilized in transient transfection assays. Figure provided by Invitrogen Life
Technologies.
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The expression plasmid containing the entire DAX-1 coding sequence was
previously generated by Dr. Tzagarakis-Foster. Briefly, the entire DAX-1 coding sequence
was amplified by PCR and cloned into the plasmid using the BamHI and XhoI restriction
enzyme sites. The insert was ligated into the appropriate vector and transformed into E.coli.
Transformants were selected on LB (Luria-Bertani) plates containing 50-100 µg/mL of
ampicillin. The transformants were then selected for the presence of insert by restriction
digestion. The transformants were selected with the correct restriction pattern and
confirmation of the correct insertion of DAX-1 into pcDNA3.1 in the proper orientation
was confirmed by DNA sequencing. The construct was then transfected into a mammalian
cell line of interest and the expression of the recombinant gene DAX-1 was tested by
western blot analysis or PCR functional assays.
Empty pcDNA 3.1 plasmid (Life Technologies, Carlsbad, CA) or pcDNA 3.1
plasmid containing the wild-type DAX-1 DNA sequence (previously generated by Dr.
Tzagarakis-Foster) was transfected into PC3 cells previously seeded in six well plates using
a range of concentrations (1-5µg) of plasmid with 50µL of Lafectine RU50 transfection
reagent (MednaBio, Burlingame, CA). Optimal plasmid concentration for simulating
physiological expression of DAX-1 in PCa cells was determined to be 3µg. Cells were
incubated for 24-48 hours and collected for total RNA isolation and whole cell protein
lysate. Successful knock-in was verified with PCR and qPCR for mRNA levels, and
Western Blot and Immunofluorescence for protein levels. Samples from successful DAX-1
knock-in transfections are referred to as “PC3+DAX-1” hereinafter.

EdU Assay
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The Click-iT® EdU Alexa Fluor 488 Flow Cytometry Assay Kit (Invitrogen,
Carlsbad, CA) was used according to manufacturer’s protocol. Briefly, cells were seeded
into 6-well plates and starved in 1% FBS media for 24 hours prior to treatments with Mb.
Mb treatments were conducted as previously described after 24-hour starvation. 24 hours
post-Mb treatments, media was replaced with EdU containing media at a concentration of
10µM and Mb treatments repeated. Cells from the same population not treated with EdU
were included as a negative staining control. Cells were harvested and washed with 1%
Bovine serum albumin (BSA) in Phosphate-buffered saline (PBS). Cells were pelleted with
centrifugation at 1,000 rpm and supernatant was removed. Pellets were dislodged and 100µl
of Click-iT® fixative (Invitrogen, Carlsbad, CA) was added and mixed. Cells were
incubated for 15 minutes at room temperature, protected from light. Cells were washed
with 1% BSA in PBS, pelleted, and the supernatant removed. Cells were re-suspended in
100µL of 1X Click-iT® saponin-based permeabilization and wash reagent (Invitrogen,
Carlsbad, CA), mixed, and incubated for 15 minutes protected from light. A 500µL total
Click-iT® reaction cocktail for 1 reaction was prepared adding the reagents in the following
order (this was necessary for the click reaction to occur although it was not stated in the
protocol for Flow Cytometry but mentioned in other Click-iT EdU protocols): 438µL of
PBS, 10µL of CuSO4, 2.5µL of the fluorescent dye azide Alexa Fluor 488, and 50µL of a
1X Click-iT® EdU buffer additive. 500µL of Click-iT® reaction cocktail was added to each
tube for reaction and mixed well. The reaction mixture was incubated for 30 minutes at
room temperature, protected from light. Cells were washed with 1X Click-iT® saponinbased permeabilization and wash reagent, pelleted, and supernatant removed. Cells were
finally re-suspended in 500µL of 1X Click-iT® saponin-based permeabilization and wash
reagent and analyzed with a flow cytometer.
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Flow Cytometry
After EdU staining and completing the Click-iT® EdU Alexa Fluor 488 Flow
Cytometry Assay protocol, cells were quantified using the BD Accuri C6 Cytometer and
the provided BD Accuri C6 Plus software computer program, with a sample size of 10,000
cells per reading.

Statistical Analysis
Statistical significance was calculated using the two-tailed t-test formula built
into Microsoft Excel. Data was found to be statistically significant if p< 0.05.
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Results
Analysis of proliferation markers post-Mb treatments in LnCap cells
As mentioned in Chapter 2, the expression of AR did not change across Mb treated
samples, while DAX-1 expression was up-regulated in LnCap cells after Mb treatment as
verified by standard PCR run through an agarose gel. All proliferation markers appeared to
be down-regulated with Mb treatments (Figure 3-8 A). The most significant downregulation was observed in the proliferation markers PCNA and Ki67. PCNA was observed
to decrease in a dose-dependent manner, while Ki67 seemed to be down-regulated more at
some concentrations than others with no discernable pattern. The cyclins involved in the
G1/S transition of the cell cycle, Cyclin D1, Cyclin A, and Cyclin E were observed to
decrease in expression with Mb treatments in a semi-dosage dependent manner. Cyclin B1
was observed to increase in expression at low concentrations of Mb and decrease in
expression at high concentrations. The expression of GAPDH did not change in any
treatments and was used as a positive control. These results were quantified with qPCR
analysis (Figure 3-8 B). Similar to the results of standard PCR, the expression of all
proliferation markers was down-regulated with Mb treatments. All of the cyclins involved
in the G1/S transition of the cell cycle, as well as the proliferation markers PCNA and
Ki67, were observed to decrease in a dosage-dependent manner. The most significant
down-regulation was observed for Cyclin E and the proliferation marker Ki67. Cyclin B1
expression was also down-regulated with Mb treatments. Interestingly, Cyclin B1
expression was down-regulated to the greatest level with the slowest Mb concentration of
100pM and returned to concentrations closer to those of untreated samples with higher Mb
concentrations. GAPDH was used as a baseline when experimental genes were compared
across treatments.
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Figure
3-8. Expression of proliferation markers post-Mb treatments in LnCap cells.
A. Agarose gel electrophoresis of PCR samples comparing the expression of proliferation
markers in untreated (1%ETOH) and Mb treated LnCap cells. B. qPCR results showing
fold-change expression of proliferation markers in Mb treated samples compared to
untreated sample in LnCap cells. GAPDH was used as a control and experimental genes
were compared to GAPDH as a baseline. Fold-change values were calculated by comparing
untreated and treated samples following the D-DCt method. Error bars on qPCR results
represent standard deviation of the mean. A single asterisk (*) represents samples that were
p<0.05, a double asterisk (**) represents samples that were p<0.005, and a triple asterisk
(***) represents samples that were p<0.0005.
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Analysis of proliferation markers post-Mb treatments in PC3 cells
As mentioned in Chapter 2, PC3 cells express only negligible amounts of AR. AR
expression allows them to be sensitive to treatments with Mb, which was observed to also
lead to an increase in the expression of DAX-1 levels as verified by standard PCR run
through an agarose gel. The expression of proliferation markers did not drasticly change as
observed in LnCap Mb treatments (Figure 3-9 A). The only cyclins that were observed to
have a small degree of down-regulation were Cyclin A and Cyclin E. Almost no change
was observed in the expression of Cyclin B1. However, there appeared to be a decrease of
Cyclin B1 expression at low levels of Mb and an increase of expression at high levels of
Mb. In the case of the proliferation markers PCNA and Ki67, their expression seemed to be
down-regulated at some concentrations and unchanged at other concentrations without any
discernable pattern.
Results for the expression of proliferation markers were similar when quantified via
qPCR analysis (Figure 3-9 B). The expression of cyclins involved in the G1/S transition of
the cell cycle was decreased with Mb treatments. While significant in Cyclin D1 and Cyclin
A results, no significant change was observed in Cyclin E expression across samples.
Expression of Cyclin B1 and PCNA seemed to follow the same pattern. The expression of
Cyclin B1 and PCNA was down-regulated at low concentrations of Mb, and up-regulated at
high Mb concentrations. Finally, Ki67 exhibited the same response observed in LnCap
cells. The expression of Ki67 was significantly down-regulated in a semi-dosage dependent
manner with Mb treatments. The expression of GAPDH did not change in any treatments
and was used as a positive control. GAPDH was also used as a baseline when experimental
genes were compared across treatments.

93

A
PC3
UT(((100pM(((1nM((((10nM(((100nM(((1uM
AR

167(bp

DAX?1

122(bp

Cyclin?D1

229(bp

Cyclin?A

300(bp

Cyclin?E

204(bp

Cyclin?B1

294(bp

PCNA

452(bp

KI?67

198(bp

GAPDH

148(bp

Mb!DAX&1(regulation(of(proliferative(genes
PC3(cells
B
PC3(Mb(treatment
6

*
5

**

Relative(mRNA(expression

*
4
UT
100pM
3

1nM
10nM
100nM

**

2

**

*

Cyclin(D1

Cyclin(A

*

1uM

1

0
Cyclin(E

Cyclin(B1

PCNA

KI67

Figure 3-9. Expression of proliferation markers post-Mb treatments in PC3 cells. A.
Agarose gel electrophoresis of PCR samples comparing the expression of proliferation
markers in untreated (1%ETOH) and Mb treated PC3 cells. B. qPCR results showing foldchange expression of proliferation markers in Mb treated samples compared to untreated
sample in PC3 cells. GAPDH was used as a control and experimental genes were compared
to GAPDH as a baseline. Fold-change values were calculated by comparing untreated and
treated samples following the D-DCt method. Error bars on qPCR results represent standard
deviation of the mean. A single asterisk (*) represents samples that were p<0.05, a double
asterisk (**) represents samples that were p<0.005, and a triple asterisk (***) represents
samples that were p<0.0005.
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Analysis of proliferation markers post-Mb treatments in DU145 cells
As previously indicated in Chapter 2, DU145 cells express no significant levels of
AR but demonstrate high levels of DAX-1 expression. While AR expression was not
observed, DU145 cells appeared to be somewhat sensitive to androgens. The expression of
all proliferation markers was highly variable in standard PCR samples ran through an
agarose gel (Figure 3-10 A). Expression of Cyclin D1 and Ki67 seemed to increase and
decrease across Mb treatments without a discernable pattern. Expression of Cyclin A
remained unchanged across samples. The expression of Cyclin E appeared to be downregulated in a dosage-dependent manner. In contrast, expression of Cyclin B1 and PCNA
seemed to increase at high concentrations of Mb. Similar results were observed after
quantification with qPCR analysis (Figure 3-10 B). While not significant, expression of
Cyclin D1, Cyclin E, and Ki67 was down-regulated and up-regulated across samples
without an apparent pattern. Interestingly, the expression of Cyclin B1 and PCNA was upregulated at high concentrations of Mb. Expression of Cyclin B1 decreased at low Mb
concentrations and increased dramatically at high Mb concentrations. The expression of
GAPDH did not change in any treatments and was used as a positive control. GAPDH was
also used as a baseline when experimental genes were compared across treatments.
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Figure 3-10. Expression of proliferation markers post-Mb treatments in DU145 cells.
A. Agarose gel electrophoresis of PCR samples comparing the expression of proliferation
markers in untreated (1%ETOH) and Mb treated DU145 cells. B. qPCR results showing
fold-change expression of proliferation markers in Mb treated samples compared to
untreated sample in DU145 cells. GAPDH was used as a control and experimental genes
were compared to GAPDH as a baseline. Fold-change values were calculated by comparing
untreated and treated samples following the D-DCt method. Error bars on qPCR results
represent standard deviation of the mean. A single asterisk (*) represents samples that were
p<0.05, a double asterisk (**) represents samples that were p<0.005, and a triple asterisk
(***) represents samples that were p<0.0005.

96

CRISPR/Cas 9 DAX-1 knock-out in LnCap cells and Mb treatments in LCR1 cells
As previously stated, a CRISPR/Cas 9 mediated knock out of DAX-1 in LnCap
cells was employed to analyze the independent role of DAX-1 in regulating proliferation
markers. A stable DAX-1 KO LnCap cell line was established using CRISPR/Cas9
technology and named “LCR1”. Results for DAX-1 knock-out are illustrated in Figure 311. Expression of DAX-1 mRNA was eliminated as verified in standard PCR samples ran
through an agarose gel (Figure 3-11 A) and quantified with qPCR analysis (Figure 3-11 B).
In the same manner, protein expression of DAX-1 was eliminated and confirmed via
Western Blot analysis (Figure 3-11 C) and immunofluorescence analysis (Figure 3-11 D).
The LCR1 cell line was also treated with increasing concentrations of Mb and the
expression of DAX-1 was analyzed. As shown in Figure 3-12 A, the expression of DAX-1
was eliminated as verified by PCR amplification followed by agarose gel electrophoresis.
The expression of AR mRNA seemed to be unchanged by standard PCR analysis.
However, significant down-regulation was observed when samples were quantified via
qPCR analysis (Figure 3-12 B). The expression of GAPDH did not change in any
treatments and was used as a positive control. GAPDH was also used as a baseline when
experimental genes were compared across treatments.
Similar results were observed in Western Blot analyses. As shown in Figure 3-13,
expression of DAX-1 protein was eliminated. However, the expression of AR was downregulated in Mb treated samples following DAX-1 knockout. Expression of GAPDH
protein did not change across samples and was used as a positive control.
Finally, results from immunofluorescence studies showed the opposite trend. As
seen in Figure 3-14, the expression of AR was up-regulated with increasing concentrations
of Mb in LCR1 cells. Again, the expression of DAX-1 was undetectable.
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Figure 3-11. Results of CRISPR mediated knock-out of DAX-1 expression in LnCap
cells. A. Agarose gel electrophoresis of PCR samples comparing the expression of AR and
DAX-1 in LnCap and DAX-1 CRISPR/Cas9 knock out (LCR1) cells. B. qPCR results
showing fold-change expression of DAX-1 in LnCap and LCR1 cells. GAPDH was used as
a control and experimental genes were compared to GAPDH as a baseline. Fold-change
values were calculated by comparing LnCap and LCR1 cell samples following the D-DCt
method. Error bars on qPCR results represent standard deviation of the mean. A single
asterisk (*) represents samples that were p<0.05, a double asterisk (**) represents samples
that were p<0.005, and a triple asterisk (***) represents samples that were p<0.0005. C.
Western Blot analysis comparing AR and DAX-1 protein expression LnCap and LCR1
cells. GAPDH was used as a positive control. D. Confocal visualization of AR and DAX-1
protein expression LnCap and LCR1 cells. Nuclei were stained with DAPI. Scale bar
represents 10µm.
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Analysis of proliferation markers post-Mb treatments in LCR1 cells
As previously indicated, the expression of DAX-1 was eliminated in LCR1 cells
and no endogenous expression of DAX-1 was visible after treatments with Mb. As shown
in Figure 3-15 A, the expression of all proliferation markers was significantly increased as
verified by agarose gel electrophoresis of standard PCR samples upon Mb treatments. The
trend of the expression of proliferation genes was completely opposite to that of previously
observed trend in LnCap cells. The expression of Cyclin D1 seemed to increase with the
smallest concentration of Mb and not to change at higher concentrations. The expression of
Cyclin A and Cyclin B1 seemed to stay unchanged across Mb treatments. The expression
of Cyclin E was significantly up-regulated in Mb treated samples and untraceable in the
untreated samples. Finally, the PCNA and Ki67 proliferation markers appeared to increase
in expression in Mb treated samples in a semi dosage-dependent manner.
Similar results were observed after quantification with qPCR analysis as shown in
Figure 3-15 B. Expression of all proliferation markers increased in the Mb treated samples.
Significant up-regulation of Cyclin D1 expression was seen only in the lowest
concentration of Mb. The expression of Cyclin A and Cyclin E increased in all Mb treated
samples with no discernable pattern. Remarkably, the expression of Cyclin B1, PCNA, and
Ki67 increased in a dosage-dependent manner. PCNA and Ki67 expression showed the
most drastic and significant results. The expression of GAPDH did not change in any
treatments and was used as a positive control. GAPDH was used as a baseline when
experimental genes were compared across treatments.
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Figure 3-15. Expression of proliferation markers post-Mb treatments in LCR1 cells.
A. Agarose gel electrophoresis of PCR samples comparing the expression of proliferation
markers in untreated (1%ETOH) and Mb treated LCR1 cells. B. qPCR results showing
fold-change expression of proliferation markers in Mb treated samples compared to
untreated sample in LCR1 cells. GAPDH was used as a control and experimental genes
were compared to GAPDH as a baseline. Fold-change values were calculated by comparing
untreated and treated samples following the D-DCt method. Error bars on qPCR results
represent standard deviation of the mean. A single asterisk (*) represents samples that were
p<0.05, a double asterisk (**) represents samples that were p<0.005, and a triple asterisk
(***) represents samples that were p<0.0005.
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DAX-1 knock-in in PC3 cells
As previously described, an alternative method to analyze the individual role of
DAX-1 regulation of proliferation markers involved transiently expressing DAX-1 in a
DAX-1 negative cell line such as the PC3 cells. Figure 3-16 A shows the results of AR,
DAX-1, and Cyclin D expression after transfecting increasing amounts of plasmid into PC3
cells. Expression of AR varied across treatments and the expression of DAX-1 increased at
small concentrations of the plasmid and decreased at higher plasmid concentrations of up to
3µg. Similar results were seen in the expression patterns of the proliferation marker. The
middle range concentration of 3µg was chosen for all further transfections and the
expression of AR, DAX-1, and Cyclin D1 were again compared and evaluated to assess
reproducible results (Figure 3-16 B).
The expression of DAX-1 mRNA and protein was up-regulated post transfections of
3µg concentrations of the plasmid. The expression of DAX-1 mRNA visible in the agarose
gel electrophoresis of standard PCR samples (Figure 3-17 A) and quantified by qPCR
analysis (Figure 3-17 B) simulated endogenous physiological levels of DAX-1 expression
in LnCap cells. Similarly, expression of DAX-1 protein visible in western blot analyses
(Figure 3-17 C) and immunofluorescence studies (Figure 3-17 D) also mirrored
endogenous physiological levels. Transfections of 3µg of DAX-1 pcDNA plasmid were
used to analyze the effects of DAX-1 in the expression of proliferation markers.
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Figure 3-16. DAX-1 pcDNA transfections into PC3 cells. A. qPCR analyses for foldchange expression of AR, DAX-1, and the proliferation marker Cyclin D1 after DAX-1
knock-in in PC3 cells using increasing concentrations of pcDNA plasmid. B. qPCR
analyses for fold-change expression of AR, DAX-1, and Cyclin D1 after DAX-1 knock-in
in PC3 cells with 3µg of plasmid, confirming reproducibility of experiments and stable
expression of markers. GAPDH was used as a control and experimental genes were
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compared to GAPDH as a baseline. Fold-change values were calculated by comparing
untreated and treated samples following the D-DCt method. Error bars on qPCR results
represent standard deviation of the mean. A single asterisk (*) represents samples that were
p<0.05, a double asterisk (**) represents samples that were p<0.005, and a triple asterisk
(***) represents samples that were p<0.0005.
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Figure 3-17. DAX-1 mRNA and protein expression analyses in PC3 cells post pcDNA
DAX-1 transfection. A. Agarose gel electrophoresis of PCR samples comparing the
expression of AR and DAX-1 in UT and +DAX-1 PC3 cells. B. qPCR results showing
fold-change expression of DAX-1 in UT and +DAX-1 PC3 cells. GAPDH was used as a
control and experimental genes were compared to GAPDH as a baseline. Fold-change
values were calculated by comparing UT and +DAX-1 cell samples following the D-DCt
method. Error bars on qPCR results represent standard deviation of the mean. A single
asterisk (*) represents samples that were p<0.05, a double asterisk (**) represents samples
that were p<0.005, and a triple asterisk (***) represents samples that were p<0.0005. C.
Western Blot analysis comparing AR and DAX-1 protein expression in UT and +DAX-1
PC3 cells. GAPDH was used as a positive control. D. Confocal visualization of AR and
DAX-1 protein expression in UT and +DAX-1 cells. Nuclei were stained with DAPI. Scale
bar represents 10µm.
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Analysis of proliferation markers in DAX-1+ PC3 cells
As expected, DAX-1 expression down-regulated the mRNA expression of most of
the proliferation markers as verified by agarose gel electrophoresis of standard PCR
samples (Figure 3-18 A) and quantified via qPCR analysis (Figure 3-18 B). All of the
cyclins involved in the G1/S progression of the cell cycle were down-regulated when DAX1 was present. Similarly, the expression of the proliferation markers PCNA and Ki67
drastically decreased when DAX-1 was present. In contrast, the expression of Cyclin B1
was significantly up-regulated when DAX-1 was present. Parallel results were seen in the
qPCR analysis. The expression of all the cyclins involved in the G1/S transition of the cell
cycle was down-regulated significantly. Similarly, the expression of the proliferation
markers PCNA and Ki67 was down-regulated when DAX-1 was present. The expression of
Cyclin B was up-regulated in the presence of DAX-1. Finally, the expression of the empty
vector was negligible across samples with the exception of PCNA and Ki67 where a small
upregulation was observed. When omitted, the expression of PCNA and Ki67 proliferation
markers can be estimated to further decrease. The expression of GAPDH did not change in
any treatments and was used as a positive control and as a baseline when experimental
genes were compared across treatments.
Similar results were observed for the protein expression of proliferation markers
through western blot analysis (Figure 3-19). The protein expression of all the proliferation
markers was down-regulated when DAX-1 was present with the exception of Cyclin B1.
While the mRNA expression of Cyclin B1 seemed to be up-regulated in PCR and qPCR
analyses, protein expression of Cyclin B was not observed to change in western blot
analyses. GAPDH expression was used as a positive control in protein expression assays.
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Figure 3-18. mRNA expression of proliferation markers in DAX-1+ PC3 cells. A.
Agarose gel electrophoresis of PCR samples comparing the expression of proliferation
markers in untreated (Lafectine) and pcDNA DAX-1 transfection of 3ug plasmid in PC3
cells. B. qPCR results showing fold-change expression of proliferation markers in UT
samples compared to an empty vector and to DAX-1 + PC3 cells. GAPDH was used as a
control and experimental genes were compared to GAPDH as a baseline. Fold-change
values were calculated by comparing untreated and treated samples following the D-DCt
method. Error bars on qPCR results represent standard deviation of the mean. A single
asterisk (*) represents samples that were p<0.05, a double asterisk (**) represents samples
that were p<0.005, and a triple asterisk (***) represents samples that were p<0.0005.
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Analysis of proliferation using the EdU Click-iT® proliferation assay in LnCap, LCR1, and
DAX-1+ PC3 cells
The EdU Click-iT® proliferation assay was used to measure the proliferation rates
in LnCap and LCR1 cells with Mb treatments, and the PC3 cells post DAX-1 transfections.
As shown in Figure 3-20, the proliferation rates for LnCap cells were not unusually high, as
observed in cell culture. The proliferation rate in untreated samples was approximately
30%. After treatments with Mb, those proliferation rates decreased by almost 10%. Results
from Mb treatments did not seem to decrease in a dosage-dependent manner, and AR
activation with Mb was sufficient to decrease proliferation rates in LnCap cells.
A radical change was observed in the proliferation rates of CRISPR DAX-1
negative LCR1 cells. The proliferation rates for untreated samples exhibited a mean
proliferation rate of almost 60%, a drastic increase when compared to that of the WT
LnCap cell line. As expected, the proliferation rates of these cells increased even further
with Mb treatments when DAX-1 was absent. The results of increased proliferation rates of
LCR1 cells observed with the EdU Click-iT® proliferation assay were similar to the
increased proliferation observed in cell culture.
Finally, there was no significant change in the proliferation rates of DAX-1+ PC3
cells. While the proliferation rates did decrease with expression of DAX-1 after knock-in,
results were not significant. Interestingly, but beyond the scope of this thesis, re-expression
of AR into the AR negative cell line PC3 did significantly decrease their proliferation rates.
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Figure 3-20. EdU proliferation assay in LnCap cells post Mb treatments. A. Flow
cytometry histogram of EdU stained LnCap cells in untreated (1%ETOH) and post
increasing concentrations of Mb. The figures show a clear separation of proliferating cells
which have incorporated EdU and non-proliferating cells which have not. B. Bar graph
representing the mean percentage of cells stained with EdU in 3 independent experiments
in UT and Mb treated LnCap cells. Error bars on results represent standard deviation of the
mean. A single asterisk (*) represents samples that were p<0.05, a double asterisk (**)
represents samples that were p<0.005, and a triple asterisk (***) represents samples that
were p<0.0005.

112

A
1nM

100pM

UT

10nM

100nM

1uM

Metribolone concentration

B
Alexa"Fluor"488"EdU Flow"Cytometry"in"LCR1"cells
*
**
100

%"of"cells"stained"(EdU)

90

81.2

87.3

83.8

80
70
60

75.0

73.5

100nM

1uM

57.3

50
40
30
20
10
0
UT

100pM

1nM

10nM

Metribolone"concentration

Figure 3-21. EdU prloliferation assay in LCR1 cells post Mb treatments A. Flow
cytometry histogram of EdU stained LCR1 cells in untreated (1%ETOH) and post
increasing concentrations of Mb. The figures show a clear separation of proliferating cells
which have incorporated EdU and non-proliferating cells which have not. B. Bar graph
representing the mean percentage of cells stained with EdU in 3 independent experiments
in UT and Mb treated LCR1 cells. Error bars on results represent standard deviation of the
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Figure 3-22. EdU proliferation assay in DAX-1+ PC3 cells A. Flow cytometry histogram
of EdU stained PC3 cells in untreated (Lafectine) and post DAX-1 and AR pcDNA
transfections. The figures show a clear separation of proliferating cells which have
incorporated EdU and non-proliferating cells which have not. B. Bar graph representing the
mean percentage of cells stained with EdU in 3 independent experiments in untreated and
treated PC3 cells. Error bars on results represent standard deviation of the mean. A single
asterisk (*) represents samples that were p<0.05, a double asterisk (**) represents samples
that were p<0.005, and a triple asterisk (***) represents samples that were p<0.0005.
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Discussion
The regulation of key proliferation markers after treatments with the nonaromatizable androgen Mb was explored in this chapter. Given the changes in the
expression of proliferation markers and the up-regulation of DAX-1 after Mb treatments,
the individual regulation of proliferation markers attributed to DAX-1 was explored
through the use of knock-out and knock-in studies. The effects of the androgen-induced
transcription factor DAX-1 on regulating the proliferation of prostate cancer cells could
create new insights into the potential detrimental effects of ADT.

Modulation of proliferation by AR in prostate cancer cells
As previously mentioned, testosterone can be aromatized into estradiol by the p450aromatase enzyme thereby activating ER. Consequently, some of the detrimental effects
observed in prostate cancer when androgens are present could be attributed to the effects of
p450 aromatase and estradiol. Hence, research exploring the sole effects of AR activation
on regulating proliferation markers and proliferation rates in prostate cancer is important
and necessary.
A great majority of proliferation markers were down-regulated after Mb treatments
in all three cell lines. In LnCap cells, all the cyclins involved in the G1/S transition of the
cell cycle, Cyclin B1 (G2/M transition of the cell cycle), and the proliferation markers
PCNA and Ki67 were down-regulated when Mb was present. Some down-regulation was
observed to occur in a dosage-dependent manner. In PC3 cells that express only negligible
amounts of AR and DAX-1, expression of some proliferation markers was down-regulated
and varied across treatments. Mb alone appeared to be sufficient to decrease the expression
of key proliferation markers. ADT prevents the inhibitory effects of AR over key
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proliferation markers, such as Cyclins involved in the G1/S phase of the cell cycle and
Ki67. Hence, other studies are needed to analyze the most beneficial course of treatment for
PCa. Because we observe beneficial outcomes in prostate cancer cells when activating AR
only, focus must be taken into considering other markers that influence proliferation of
cancer cells, such as ER. In addition, the downstream targets involved in the AR or ER
pathways are essential to cell behavior. Therefore, downstream markers could pose a better
target for cancer treatments than AR and ER themselves, which are modulators of various
genes.
The variable effects on the regulation of proliferation markers across the three cell
lines are indicative of the differential effects the varied amount of hormone receptors across
cell lines have on cell fate. The expression of DAX-1 observed in LnCap cells after
treatments with Mb seemed to create the optimal setting for a decrease in proliferation. In
contrast, the highly increased expression of DAX-1 in DU145 cells observed across
samples regardless of Mb treatments as well as their effects on proliferation markers could
be indicative of the same dosage sensitiveness to DAX-1 expression. Extremely high
amounts of DAX-1 gene product could possibly negate DAX-1’s beneficial role in prostate
cancer cells.

Modulation of proliferation by DAX-1 in prostate cancer cells
As previously stated, two methods were employed to determine the independent
role of DAX-1 in regulating proliferation markers. Through CRISPR/Cas 9 mediated knock
out of DAX-1 in LnCap cells, we were able to analyze the effects of Mb treatments on the
expression of proliferation genes when DAX-1 was not present. In addition, transient
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expression of DAX-1 in the DAX-1 negative PC3 cell line allowed to examine the changes
in the expression of the proliferation markers when DAX-1 was present.
After establishing the DAX-1 negative Lncap cell line LCR1, treatments with Mb
were performed in order to analyze whether high Mb treatments had an effect on AR
expression, and if DAX-1 expression was perceived at any drug concentration. No DAX-1
expression was seen across treatments as expected. However opposite results were
observed in the evaluation of AR expression in the mRNA and protein levels. Overall, AR
down-regulation was observed when Mb was present. This could point to a possible
regulation of DAX-1 protein over an AR co-repressor. Alternatively, the opposing effects
of AR expression in protein studies could indicate a dual effect of DAX-1 over AR
expression. While potentially acting as a negative modulator of certain AR co-repressors,
such as p450 aromatase previously detailed by Lanzino et al. [36], DAX-1 could also act as
a negative modulator of AR enhancers. A certain balance of AR regulation could then be
proposed for the dual effects DAX-1 has on AR expression in PCa cells.
To assess DAX-1 regulation of proliferation markers, the LCR1 cell line was also
treated with Mb. A striking increase in the expression of proliferation markers was
observed in LCR1 cells when compared to LnCap cells. Addition of Mb increased the
expression of proliferation even further. Consequently, an overall opposite trend on the
expression of proliferation markers was observed in LCR1 cells. These experiments
provided evidence of the beneficial effects of DAX-1 as a negative modulator of the
expression of proliferation markers. The alternative method used to analyze the individual
role of DAX-1 in regulating the expression of proliferation markers involved transfections
of DAX-1 plasmid to transiently express endogenous physiological levels of DAX-1 in
PC3 cells. These results also contributed proof to the beneficial and detrimental effects that
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DAX-1 present in a cell can have, depending on its dose. Accordingly, this outcome shows
evidence of the diverse effects that different doses of DAX-1 gene product available in a
cell have in the regulation of AR and proliferation markers.
DAX-1 appears to be a transcriptional repressor of genes associated in the G1/S
transition of the cell cycle. These results provide confirmation of the repressive role DAX-1
plays in the regulation of key markers of proliferation in prostate cancer cells. In addition,
these conclusions further corroborate the notion that ADT prevents the expression of
markers that are beneficial to prevent cancer proliferation, such as DAX-1. Therapies aimed
at genes that only allowed for cell proliferation could provide more efficient than ADT,
which targets a gene that modulates many downstream targets.

DAX-1 and AR regulation of proliferation rates in prostate cancer cells
DAX-1 seems to act as a negative modulator of proliferation markers in prostate
cancer cells. However, proliferation assays are necessary to examine whether DAX-1 is
sufficient to decrease the proliferation of prostate cancer cells. The results shown from the
proliferation assays were parallel to their growth behavior in cell culture. In contrast, the
proliferation rates observed in the LCR1 cell line were twice as fast as those observed in
LnCap cells. This was expected, due to the repressive properties DAX-1 exhibits over
proliferation markers and the increased expression of proliferation markers observed in
LCR1 cells. In contrast to the decreased proliferation rates observed in LnCap cells when
Mb was added, proliferation rates increased significantly when Mb was added to LCR1
cells. These results further validate the benefits of DAX-1 expression in prostate cancer
cells. Without the presence of DAX-1 to down-regulate proliferation markers, AR
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activation very significantly increased the proliferation rates of LCR1 cells. Thus, DAX-1
appears to have a pivotal role in the proliferation of prostate cancer cells.
Finally, the proliferation rates in DAX-1 negative and DAX-1 positive PC3 cells
were explored to analyze whether DAX-1 expression is sufficient to decrease proliferation
rates in these cells. Proliferation assays showed that there was a small decrease in the
proliferation rates of these cells when DAX-1 was present. However, results were not
significant. One reason could be the dissimilar expression of genes exhibited by PC3 cells
when compared to LnCap. Because PC3 cells do not express significant amounts of AR,
AR was also introduced to these cells and their proliferation rate was measured.
Interestingly, the rates of proliferation of these cells when AR was present were
significantly decreased. These results are similar to the inhibition of proliferation in PC3
cells observed by Yean et al. after androgen receptor complementary DNA transfections
[45]. These results provide evidence of certain beneficial effects of AR expression in the
proliferation rates of cells that exhibit similar properties to those of PC3 cells. The
divergent efficacy by DAX-1 on inhibiting proliferation in PC3 and LnCap cells depends
on the expression of other markers across each cell line. This could be taken into account
when dealing with treatments on patients. Not all patients exhibit the same markers, and
thus a limited treatment such as ADT is fallacious.
Throughout this chapter, the beneficial effects that DAX-1 has on the proliferation
of prostate cancer cells were uncovered. While insufficient to decrease the proliferation
rates of prostate cancer cells on its own, loss of DAX-1 expression radically increased the
proliferation rates in prostate cancer cells. In addition, the effects of sole AR activation and
sole DAX-1’s effect on proliferation was observed. AR activation also led to a slight
decrease in the proliferation rates of cells. The effects of AR and DAX-1 on proliferation
119

rates exhibited the expected behavior of cells after the changes in proliferation markers
were observed. In order to analyze whether there is a direct regulation of AR or DAX-1 on
the transcription of these examined proliferation targets, ChIP and Luciferase studies are
necessary. Moreover, the expression of proliferation markers and proliferation rates were
reduced in AR positive cells treated with Mb. These results provide evidence for how the
combined dose of AR and DAX-1 could potentially determine the outcome of proliferation
in prostate cancer cells. A time course assay analyzing the expression of AR and DAX-1
coupled with proliferation assays could determine the pivotal role of their interactions on
proliferation regulation. The results described in this chapter provide evidence of the
detrimental effects of ADT. While ADT aims to reduce AR activation in prostate cancer, it
negates the alternate effects of ER and PR action on regulating the proliferation of cancer
cells. While beneficial at first, the unbalanced action of other receptors could be the major
contribution to CRPC. In view of the beneficial effects the downstream targets of AR, such
as DAX-1, have on the progression of prostate cancer, alternative therapies are needed.
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Chapter 4
Regulation of apoptosis by AR and DAX-1 in prostate cancer cells
Introduction
Deregulated cell proliferation coupled with apoptosis or programmed-cell death
suppression are the main factors that allow for cancer cell growth. The ability of cancer
cells to evade apoptosis is one of the key components that allows cancer progression. A
thorough analysis of the effects of AR activation and transcriptional repressors, such as
DAX-1, on apoptosis regulation in prostate cancer cells will result in a better understanding
of whether ADT is the best therapeutic route for PCa. The role of AR and DAX-1
regulation of essential apoptotic and anti-apoptotic markers will be evaluated in this
chapter.
Multiple studies have been conducted to examine the role androgens and AR have
on regulating apoptosis in the context of prostate cancer. Some studies suggest that ADT
has no effect on increasing the apoptotic rates of prostate cancer cells. A histochemical
analysis of human prostate tumors 7 days after oriectomy showed that castration had no
effect or even reduced the rate of apoptosis [101]. An independent study showed that
androgen deprivation only resulted in a 3.4% apoptotic index [102]. Clinical and animal
PCa data suggest that a large part of prostate tumors are resistant to apoptosis induced by
androgen ablation. These findings could provide evidence that some of the benefits of ADT
at the time of treatment are determined by a decrease in the proliferation of tumor cells.
However, whether this is a prolonged effect of ADT is uncertain and remains to be
determined.

The Cell cycle and apoptosis
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As described in the previous chapter, two families of genes, the cip/kip and the
INK4a/ARF families are able to prevent the progression of the cell cycle and are commonly
referred to as cell cycle inhibitors. The genes p21, p27, p57, p16, and p53 are able to halt
the cell cycle and function as tumor suppressors [66]. Because cellular context is critical,
these proteins can serve to tie apoptosis to proliferation. Even though they may not be part
of the cell's apoptotic machinery, cell cycle inhibitors are indirectly involved in apoptosis.
It is possible that these proliferative proteins act to sensitize cells to apoptosis. Studies have
shown that some cell cycle inhibitors can have both anti-apoptotic and apoptotic properties.
Overexpression of p21 in mammary tumor cells has been shown to increase apoptosis
[103]. In addition, overexpression of p21 has also been shown to induce the pro-apoptotic
protein BAX, inducing apoptosis indirectly [104]. However, several studies have shown
that p21 is able to repress apoptosis in several cell culture models [105, 106]. In contrast to
the dual roles observed for p21, p27 has been mostly associated with apoptotic induction.
While overexpression of p27 was shown to cause apoptosis in several human cell lines
[107, 108], it has further been shown to exhibit anti-apoptotic properties [109]. Similarly,
p57 has been associated with a stimulatory effect on apoptosis in some models [110] and
with anti-apoptotic behavior in others [111]. Comparably, p16 has been shown to induce
apoptosis in several cell lines [112], and also prevent drug-induced apoptosis in glioma
cells[113].
The cellular tumor antigen p53 has been studied thoroughly and has been described
primarily as a tumor suppressor protein. Cellular stress, such as chemotherapeutic drugs,
hypoxia, DNA damage by UV, γ-radiation, or nucleotide deprivation, activates P53 and
causes a G1 arrest by inducing expression of p21 and inhibition of Cyclin D/CDKs
complexes. It also plays a major role in inducing apoptosis through direct activation of
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BAX [114]. These findings suggest an indirect effect of cell cycle inhibitors on apoptosis
and that their hyper-activation or mis-regulation can lead to improper CDK activity. These
effects can be the cause of why cell cycle inhibitors induce conflicting signals for cell
division and influence the apoptotic outcome.
Figure 4-1 shows a summary of the cell cycle inhibitors and their inhibition of
diverse CDKs. While cell cycle inhibitors are not part of the apoptotic machinery, they
activate several pathways that converge toward apoptosis. They appear to function to
sensitize cells to apoptosis in cells that are receiving conflicting growth signals. Their
involvement in influencing apoptosis seems to be cell-type specific. Therefore,
understanding the influence of AR activation and DAX-1 regulation on these targets and
their effect on apoptosis in the context of prostate cancer is crucial.
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Figure 4-1. Cell cycle and cell cycle inhibitors. Genes from the cip/kip and the
INK4a/ARF families are able to prevent the progression of the cell cycle and are commonly
referred to as cell cycle inhibitors.
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Pathways to apoptosis- the BCL2 family
The cellular pathways that contribute to apoptosis can be either intrinsic or extrinsic
[115]. Extrinsic pathways involve extracellular activation of death receptors at the plasma
membrane, such as TNF, that lead to caspase activation. Intrinsic pathways involve the
release of cytochrome C from the mitochondria, regulated by apoptotic or anti-apoptotic
genes such as BAX and BAD or the Bcl-2 family respectively [116, 117]. Release of
cytochrome C into the cytosol promotes caspase activation that leads to the degradation of
cellular components and prompts the cell to undergo apoptosis [116]. The Bcl-2 family
plays a central role in influencing apoptosis. Members of the Bcl-2 family lie upstream of
irreversible cellular damage and function mainly at the mitochondrial level. While the
members of the Bcl-2 family include pro- and anti-apoptotic molecules, the members
investigated throughout this chapter have been associated with anti-apoptotic properties.
Bcl-2 is located predominantly in the outer mitochondrial membrane and it appears
to prevent apoptosis by blocking the release of cytochrome c from the mitochondria [118121]. Similarly, Bcl-xl has been implicated in cell survival by inhibiting the function of p53
and cytochrome c release from the mitochondria [122, 123]. Bcl2-A1 has been shown to be
highly expressed in a variety of cancers and to contribute to cell survival in advanced
tumors [124, 125]. Finally, Bcl2-L10 has also been found to be overexpressed in some
cancers and to act as an anti-apoptotic regulator [126, 127]. While the exact mechanism by
which some of these anti-apoptotic targets operate is unknown, they all seem to prevent
apoptosis through inhibition of cytochrome c release from the mitochondrion or through
inhibition of the tumor suppressor protein p53. Figure 4-2 summarizes the mechanistic
pathway for apoptosis, integrating the roles of p53 which were previously described and the
Bcl-2 family members.
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Figure 4-2. Apoptosis regulation by p53 and the Bcl-2 family. Cellular stress such as
DNA damage, deprivation of growth factors or chemotherapeutics can induce p53
activation. P53 can activate BAX and BAK proteins that cause mitochondrial membrane
permeabilization and release of cytochrome c that causes caspases activation and leads with
apoptosis. Members of the Bcl-2 family are able to prevent cytochrome c release through
direct or indirect regulation of BAX and BAK proteins.
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AR and DAX-1 on apoptosis
The androgen receptor plays a central role in the progression of prostate cancer.
Consequently, its role in influencing apoptosis has been the focus of many PCa related
studies. Elevation of the anti-apoptotic proteins Bcl-2, Bcl-x, and mcl-1 has been found in
prostatic intraepithelial neoplasia [128, 129]. Their expression was also found to increase
with prostate cancer progression [128, 129]. Furthermore, overexpression of Bcl-2 has been
associated with the enhancement of tumor formation in castrated male mice [26].
Additionally, androgen deprivation has been shown to enhance Bcl-2 expression in cell line
models [27]. These findings suggest that the elevated expression of anti-apoptotic proteins,
such as Bcl-2, is central to influencing apoptosis survival in prostate cancer. An alternative
regulation for the over-expression of anti-apoptotic proteins can be associated with growth
factors. The androgen-induced fibroblast growth factor 2 (FGF2) has been associated with
promoting growth and survival of prostate cancer cells by up-regulating the expression of
Bcl-2 [130]. Further studies investigating AR regulation of apoptotic and anti-apoptotic
genes in addition to growth factors are necessary in order to discern the pathways that lead
to prostate cancer progression.
The role DAX-1 has on influencing apoptosis in PCa has not been thoroughly
investigated. Previous research in Dr. Tzagarakis Foster’s Laboratory (unpublished) in
breast cancer cells has suggested that DAX-1 has some impact on down-regulating proteins
like Bcl-2, Bcl-xl, and TNFα, which are associated with cell survival. Similarly, DAX-1
was shown to increase the expression of pro-apoptotic genes, like BAX, BAD, Bcl-XS,
Bcl2-l1, and TRAF3 (unpublished). Moreover, a study has explored how DAX-1
knockdown increased the expression of more than 90% of genes that control cell
proliferation and apoptosis in multiple tissues [131]. While the role DAX-1 plays in
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regulating apoptosis in the context of prostate cancer remains unknown, the studies in this
chapter will provide data linking DAX-1 and AR to the regulation of apoptosis in prostate
cancer cells. As shown in Figure 4-3, we expect that DAX-1 will down-regulate the
expression of anti-apoptotic markers and induce the expression of cell cycle inhibitors
indirectly.
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Figure 4-3. Putative regulation of apoptotic markers by DAX-1 in prostate cancer
cells. As a transcriptional repressor, DAX-1 potentially down-regulates the expression antiapoptotic markers. However, we expect that DAX-1 up-regulates the expression of cell
cycle inhibitors indirectly.
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Materials and Methods
Reagents
Metribolone (Mb) was used for cell treatments using the same protocol described in
Chapter 2.

RNA extraction and cDNA synthesis
RNA extraction and cDNA synthesis was performed as described in Chapter 2
using the RNeasy Mini Kit (Qiagen, Valencia, CA) as per the manufacturer's instruction,
with the optional RNase-Free DNAse (Qiagen) step added to remove genomic DNA
contamination. The QuantiTect Reverse Transcription Kit (Qiagen) was used to synthesize
cDNA from the isolated RNA according to manufacturer's instructions.

PCR
cDNA synthetized from extracted mRNA was used as a template for standard PCR
and PCR reaction samples were prepared as described in Chapter 2. Primers used for
proliferation targets are summarized in Table 3-1. Following PCR, samples were
electrophoresed through a 2% 1X TAE agarose gel (Thermo Scientific, Wilmington, DE)
containing EtBr (Biorad, Hercules, CA) at 0.5 µg/mL final concentration, usually about 2µl
per 100mL gel. PCR products were visualized under ultraviolet light exposure using the
BioRad GelDoc System (BioRad, Hercules, CA). Images are representative of five
independent experiments.

Quantitative PCR (qPCR)
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cDNA was synthetized from extracted mRNA and was used as a template for qPCR.
qPCR reactions were performed as described in Chapter 2. Primers used for cell cycle
inhibitors and anti-apoptotic targets are summarized in Table 4-1. GAPDH housekeeping
gene was used as control and experimental genes were compared to GAPDH as a baseline.
Fold-change values were calculated by comparing untreated and treated samples following
the ∆-∆Ct method. Error bars on qPCR results represent standard deviation of the mean.
Images are representative of five independent experiments.

Table 4-1. List of Primers used for standard PCR and two-step amplification qPCR.
Gene
Name
Housekeeping
gene

GAPDH

Target

DAX-1
P16
P27

Cell cycle
inhibitors

P21
P57
P53 exon
2+3+4
BCL2

Anti-apoptotic
genes

BCLXL
BCL2L10
BCL-2A1

Forward Primer 5’-3’

Reverse Primer 5’-3’

CCATCACCATCTTCCA
GGAGCG
GGGTAAAGAGGCGCT
ACCAG
TTATTTGAGCTTTGGT
TCTG
TCCGGCTAACTCTGAG
GACAC
AGCAGAGGAAGACCA
TGTGGAC
ATTTTCATCGCGGACT
CTGG
CAGTCAGATCCTAGCG
TCGAG
CTGCACCTGACGCCCT
TCACC
GATCCCCATGGCAGCA
GTAAAG
GCCTTCATTTATCTCT
GGACACG
CCCGGATGTGGATACC
TATAAG

AGAGATGATGACCCTT
TTGGC
GCTTGATTTGTGCTCG
TGGG
CCGGCTTTCGTAGTTT
TCAT
TGTTTTGAGTAGAAGA
ATCGTCGGT
TTTCGACCCTGAGAGT
CTCCA
TAAGAGAGACAGCGA
AAGCGC
TGCAAGTCACAGACTT
GGCTGT
CACATGACCCCACCGA
ACTCAAA
CCCCATCCCGGAAGAG
TTCATTC
GAAGGTGCTTTCCCTC
AGTTCTT
GTCATCCAGCCAGATT
TAGGTTC

Annealing
Temperature
58ºC
56ºC
54ºC
48ºC
58ºC
48ºC
54ºC
54ºC
53ºC
54ºC
56ºC

Protein Isolation
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Whole cell protein lysate was collected as described in Chapter 2 following 48-hour
treatments.
Western Blot
Western blots were performed using the Xcell II Blot Module (Invitrogen, Carlsbad,
CA) according to the NuPAGE Novex Bis-Tris Protocol (Invitrogen, Carlsbad, CA) as
described in Chapter 2. Antibodies used for Western Blot are summarized in Table 4-2.
Images are representative of three independent experiments.

Table 4-2. Antibodies used for Western Blot
Protein
GAPDH
DAX-1
P21
P27
BCL-2
BCL2-L10

Species
Rabbit (polyclonal)
Mouse (monoclonal)
Rabbit (polyclonal)
Rabbit (polyclonal)
Rabbit (polyclonal)
Rabbit (polyclonal)

Company
Cell Signaling, Danvers, MA
Active Motif, Carlsbad, CA
GeneTex, Irvine, CA
GeneTex, Irvine, CA
GeneTex, Irvine, CA
GeneTex, Irvine, CA

CRISPR/Cas9- mediated DAX-1 knockout in LnCaP cells
The stable CRISPR/Cas9-mediated DAX-1 KO cell line LCR1 was used for
experiments evaluating the regulation of AR and DAX-1 on apoptotic and anti-apoptotic
markers.

DAX-1 knock-in into PC3 cells using pcDNA3.1-DAX-1 construct
Transfections to knock-in DAX-1 expression on PC3 cells were performed as
described in Chapter 3.
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Annexin/PI
The FITC Annexin V/Dead Cell Apoptosis Kit with FITC Annexin V and PI for
flow cytometry can be used as a convenient assay for measuring apoptosis. The
recombinant Annexin V conjugated to fluorescein (FITC Annexin V), and the redfluorescent propidium iodide (PI) (a dye that binds nucleic acids) are used to distinguish
apoptotic from necrotic cells in a population. As shown in Figure 4-4, PI is unable to enter
live cells and pre-apoptotic cells, but readily stains apoptotic and dead cells with red
fluorescence, binding tightly to the cell’s nucleic acids. Apoptosis can be distinguished
from necrosis, or accidental cell death, by some morphological and biochemical changes.
These include compaction and fragmentation of the nuclear chromatin, loss of membrane
asymmetry, and shrinkage of the cytoplasm [132-135]. In live cells, phosphatidylserine
(PS) is a protein located on the cytoplasmic surface of the cell membrane. However, during
apoptosis, PS is translocated from the inner surface to the outer surface of the plasma
membrane and becomes exposed to the external cellular environment. During lymphocyte
apoptosis, PS marks cells for recognition and triggers phagocytosis by macrophages [136].
Annexin V is a human protein of 35 to 36 kDa with a high affinity for PS [137]. Annexin V
labeled with a fluorophore can therefore be used to identify apoptotic cells because of its
binding to PS on the outer surface of the plasma membrane.
10X Annexin Binding Buffer was prepared with 1M HEPES/NaOH pH 7.4, 5M
NaCl, 1M KCl, 1M MgCl2, and 1M CaCl2. Culture medium was collected in 15mL conical
tubes. Cells were washed with PBS and PBS wash was collected in 15 mL conical tubes.
Cells were trypsinized, allowed to detach and the PBS was added to collect cells. Samples
were centrifuged at 1,000 rpm for 5 minutes. Supernatant was removed and cells were re133

suspended in 1X Annexin Binding Buffer at a concentration of 1X106 cells/mL. 100µL of
solution with cells was then transferred to FACS tubes. After collection, each treatment of
cells was left unstained, stained with Annexin V alone, stained with PI alone, or stained
with the combination of Annexin V and PI. Cells were incubated in the dark for 15 minutes
at room temperature and 400µL of 1X Binding Buffer was added to each sample after
incubation. Samples were analyzed by flow cytometry within 1 hour and samples kept on
ice. The BD Acurri C6 (BD Biosciences, San Jose, CA) flow cytometer was used to
analyze samples.
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Figure 4-4. Annexin V/ PI staining of apoptotic and necrotic cells. In live cells,
phosphatidylserine (PS) is a protein located on the cytoplasmic surface of the cell
membrane. However, during apoptosis, PS is translocated from the inner to the outer
surface of the plasma membrane and PS gets exposed to the external cellular environment.
Annexin V is able to bind PS with high affinity, thereby labeling early-apoptotic cells.
Propidium Iodide (PI) is a dye unable to enter live cells. During late-apoptosis, PI is able to
enter the cell, binding tightly to the cell’s nucleic acids. Annexin V and PI can be labeled
with fluorescent dyes that can be used to quantify the percentage of cells undergoing
apoptosis in a population based on the amount of staining. Quantification is carried out by
cell flow cytometry and graphed on a computer in the BD Accuri C6 Plus software.
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Flow Cytometry
After the Annexin/PI, cells were quantified using the BD Accuri C6 Cytometer and
its provided BD Accuri C6 Plus software computer program, with a sample size of 10,000
cells per reading.

Statistical Analysis
Statistical significance was calculated using the two-tailed t-test formula built
into Microsoft Excel. Data was found to be statistically significant if p< 0.05.
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Results
Analysis of cell cycle inhibitors post-Mb treatments in LnCap cells
Analysis of the expression of cell cycle inhibitors was highly variable across cell
lines and Mb treatments. The concentration of Mb was a key effector in modifying the
expression of these markers. The most dosage-dependent response was seen in androgenresponsive LnCap cells as verified by PCR analysis (Figure 4-5 A). The expression of all
cell cycle inhibitors with the exception of p57 was observed to increase at low Mb
concentrations and decrease at high Mb concentrations. The marker p57 seemed to increase
in all Mb treated samples in a dose-dependent manner. Similar results were observed when
quantified through qPCR analysis (Figure 4-5 B). The most dramatic response was
observed on the expression of p16 where increasing concentrations of MB, resulted in
reduced expression of p16.

Analysis of cell cycle inhibitors post-Mb treatments in PC3 cells
The results observed in PC3 cells were to some extent different from those in
LnCap cells. As previously mentioned in Chapter 2, PC3 cells express almost negligible
amounts of AR. This characteristic translates to the observed change in the expression of
cell cycle inhibitors. Most of these makers were up-regulated in a dose-dependent manner
as verified by PCR analysis (Figure 4-6 A) and qPCR analysis (Figure 4-6 B). Interestingly,
the highest concentration of Mb (1µM) down-regulated the expression of all markers. This,
along with previous results in LnCap cells, indicates a Mb dose threshold that completely
changes the effects of Mb on the expression of cell cycle inhibitors.
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Figure 4-5. Expression of cell cycle inhibitors post-Mb treatments in LnCap cells. A.
Agarose gel electrophoresis of PCR samples comparing the expression of cell cycle
inhibitors in untreated (1%ETOH) and Mb treated LnCap cells. B. qPCR results showing
fold-change expression of cell cycle inhibitors in Mb treated samples compared to untreated
sample in LnCap cells. GAPDH was used as a control and experimental genes were
compared to GAPDH as a baseline. Fold-change values were calculated by comparing
untreated and treated samples following the D-DCt method. Error bars on qPCR results
represent standard deviation of the mean. A single asterisk (*) represents samples that were
p<0.05, a double asterisk (**) represents samples that were p<0.005, and a triple asterisk
(***) represents samples that were p<0.0005.
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Figure 4-6. Expression of cell cycle inhibitors post-Mb treatments in PC3 cells. A.
Agarose gel electrophoresis of PCR samples comparing the expression of cell cycle
inhibitors in untreated (1%ETOH) and Mb treated PC3 cells. B. qPCR results showing
fold-change expression of cell cycle inhibitors in Mb treated samples compared to untreated
sample in PC3 cells. GAPDH was used as a control and experimental genes were compared
to GAPDH as a baseline. Fold-change values were calculated by comparing untreated and
treated samples following the D-DCt method. Error bars on qPCR results represent standard
deviation of the mean. A single asterisk (*) represents samples that were p<0.05, a double
asterisk (**) represents samples that were p<0.005, and a triple asterisk (***) represents
samples that were p<0.0005.
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Analysis of cell cycle inhibitors post-Mb treatments in DU145 cells
The most diverse expression across Mb treated samples was observed in DU145
cells. Similar to results in PC3 and LnCap cells, the same response to low and high Mb
concentrations was observed. As shown in Figure 4-7 A, the expression of cell cycle
inhibitors increased at low Mb concentrations and decreased at the highest Mb
concentration of 1µM Mb. Intriguingly, a high concentration of Mb (100nM) increased the
expression of all cell cycle inhibitors. Similar results were observed carrying out qPCR
analyses (Figure 4-7 B). Again, low concentrations of Mb appeared to increase the
concentration of all cell cycle inhibitors. Comparably, the two highest concentrations of Mb
(100nM and 1µM) down-regulated the expression of most markers. As previously
mentioned, DU145 cells have been shown to also express negligible amounts of AR. Even
though AR expression was not detected in our experiments, the changes in the expression
of these cell cycle inhibitors reflected some response of AR. These results are reflective of
a Mb threshold that can change the expression of cell cycle inhibitors in prostate cancer
cells.
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Figure 4-7. Expression of cell cycle inhibitors post-Mb treatments in DU145 cells. A.
Agarose gel electrophoresis of PCR samples comparing the expression of cell cycle
inhibitors in untreated (1%ETOH) and Mb treated DU145 cells. B. qPCR results showing
fold-change expression of cell cycle inhibitors in Mb treated samples compared to untreated
sample in DU145 cells. GAPDH was used as a control and experimental genes were
compared to GAPDH as a baseline. Fold-change values were calculated by comparing
untreated and treated samples following the D-DCt method. Error bars on qPCR results
represent standard deviation of the mean. A single asterisk (*) represents samples that were
p<0.05, a double asterisk (**) represents samples that were p<0.005, and a triple asterisk
(***) represents samples that were p<0.0005.
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Analysis of cell cycle inhibitors post-Mb treatments in LCR1 cells
The expression of the cell cycle inhibitors did not seem to change across Mb
treatments in LCR1 cells as verified by PCR analysis (Figure 4-8 A). However, for some
markers, the opposite trend was observed when compared to WT LnCap cells. The p57
marker was observed to be down-regulated in a dosage-dependent manner. When
quantified by qPCR analysis (Figure 4-8 B), no change was observed in the expression of
cell cycle inhibitors in samples treated with the lowest concentration of Mb. However, a
significant decrease of expression was observed at 10nM, 100nM, and 1µM Mb. These
results imply that the same threshold exists for Mb dosage on the turnover of the expression
of cell cycle inhibitors. Moreover, the lack of up-regulation of cell cycle inhibitors at low
Mb concentrations in LCR1 cells could be directly attributed to the lack of DAX-1
expression in these cells after KO. Because DAX-1 is not present to up-regulate the
expression of cell cycle inhibitors, no increase in expression was observed.

142

A
LCR1
UT'''100pM'''1nM''''10nM'''100nM'''1uM
DAX31

122'bp

P16

238'bp

P21

220'bp

P27

130'bp

P53

477'bp

P57

101'bp

GAPDH

148'bp

B
LCR1'Mb'treatment
2.5

*

*

Relative'mRNA'expression

2

*

**
*

*

1.5

UT
100pM
1nM
10nM

1

100nM
1uM

0.5

0
P53

P16

P21

P27

P57

Figure 4-8. Expression of cell cycle inhibitors post-Mb treatments in LCR1 cells. A.
Agarose gel electrophoresis of PCR samples comparing the expression of cell cycle
inhibitors in untreated (1%ETOH) and Mb treated LCR1 cells. B. qPCR results showing
fold-change expression of cell cycle inhibitors in Mb treated samples compared to untreated
sample in LCR1 cells. GAPDH was used as a control and experimental genes were
compared to GAPDH as a baseline. Fold-change values were calculated by comparing
untreated and treated samples following the D-DCt method. Error bars on qPCR results
represent standard deviation of the mean. A single asterisk (*) represents samples that were
p<0.05, a double asterisk (**) represents samples that were p<0.005, and a triple asterisk
(***) represents samples that were p<0.0005.
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Analysis of cell cycle inhibitors in DAX-1+ PC3 cells
The expression of all cell cycle inhibitors except for p16 was up-regulated when
DAX-1 was transfected into PC3 cells as seen by agarose gel electrophoresis of PCR
samples (Figure 4-9 A). Quantification following qPCR analysis (Figure 4-9 B) showed the
same response. The most significant up-regulation occurred in the expression of p53, the
tumor suppressor gene known to induce the expression of p21. Consistently, the expression
of p21 was also up-regulated. The expression of cell cycle inhibitors did not significantly
change in samples treated with the empty vector and thus, change in cell cycle inhibitors is
believed to occur as a result of DAX-1 expression. Finally, western Blot analyses
demonstrate an increase in the expression of p21 and p27, consistent with PCR and qPCR
data (Figure 4-10). The expression of GAPDH did not change across treatments and was
used as a positive control. Additionally, GAPDH was used as a baseline for the expression
of targets across samples.
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Figure 4-9. mRNA expression of cell cycle inhibitors in DAX-1+ PC3 cells. A. Agarose
gel electrophoresis of PCR samples comparing the expression of cell cycle inhibitors in
untreated (Lafectine) and pcDNA DAX-1 transfection of 3ug plasmid in PC3 cells. B.
qPCR results showing fold-change expression of cell cycle inhibitors in UT samples
compared to an empty vector and to DAX-1 + PC3 cells. GAPDH was used as a control
and experimental genes were compared to GAPDH as a baseline. Fold-change values were
calculated by comparing untreated and treated samples following the D-DCt method. Error
bars on qPCR results represent standard deviation of the mean. A single asterisk (*)
represents samples that were p<0.05, a double asterisk (**) represents samples that were
p<0.005, and a triple asterisk (***) represents samples that were p<0.0005.
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Figure 4-10. Protein expression of cell cycle inhibitors in DAX-1+ PC3 cells. Western
Blot analysis comparing protein expression of cell cycle inhibitors in UT (Lafectine) and
DAX-1 + PC3 cells. GAPDH was used as a positive control.
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Analysis of anti-apoptotic markers post-Mb treatments in LnCap cells
In view of the important roles anti-apoptotic genes play in preventing programmed
cell death, members of the Bcl-2 family were also analyzed. In the androgen-sensitive cell
line LnCap, the expression of all anti-apoptotic genes was decreased in high Mb treated
samples with the exception of Bcl2-A1 and Bcl-XL (Figure 4-11 A). Bcl2-A1 was not
detected in UT or Mb treated samples with the exception of 10nM treatments. The
expression of Bcl-XL was down-regulated at very low concentrations of Mb whereas there
was no observed change at higher concentrations. However, when quantified with qPCR
analysis, there was a significant down-regulation in the expression of all markers (Figure 411 B). All Mb treatments decreased the expression of Bcl-2, Bcl2-A1, and Bcl2-L10 in a
dosage-dependent manner. Moreover, significant down-regulation of the expression of
Bcl2-XL was observed at only high Mb concentrations.
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Figure 4-11. Expression of anti-apoptotic markers post-Mb treatments in LnCap cells.
A. Agarose gel electrophoresis of PCR samples comparing the expression of anti-apoptotic
markers in untreated (1%ETOH) and Mb treated LnCap cells. B. qPCR results showing
fold-change expression of anti-apoptotic markers in Mb treated samples compared to
untreated sample in LnCap cells. GAPDH was used as a control and experimental genes
were compared to GAPDH as a baseline. Fold-change values were calculated by comparing
untreated and treated samples following the D-DCt method. Error bars on qPCR results
represent standard deviation of the mean. A single asterisk (*) represents samples that were
p<0.05, a double asterisk (**) represents samples that were p<0.005, and a triple asterisk
(***) represents samples that were p<0.0005.
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Analysis of anti-apoptotic markers post-Mb treatments in PC3 cells
The results observed in PC3 cells were variable when compared to those observed
in LnCap cells. Standard PCR experiments demonstrate no change across samples for most
of the anti-apoptotic markers (Figure 4-12 A). However, Bcl2-XL was found to be upregulated at high concentrations of Mb. A change in the expression of anti-apoptotic
markers was more discernable after qPCR analyses as shown in Figure 4-12 B. The antiapoptotic markers, Bcl-2 and Bcl2-A1, were down-regulated at low Mb concentrations and
up-regulated at higher concentrations. Interestingly, the highest concentration of Mb (1µM)
significantly decreased expression of these genes. The expression of Bcl2-L10 and Bcl2XL was up-regulated across Mb treatments in a dose-dependent manner. However, their
expression was reduced at the highest concentration of 1µM Mb. This is comparable to the
observed change in Bcl-2 and Bcl2-A1 at the highest Mb concentration.
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Figure 4-12. Expression of anti-apoptotic markers post-Mb treatments in PC3 cells. A.
Agarose gel electrophoresis of PCR samples comparing the expression of anti-apoptotic
markers in untreated (1%ETOH) and Mb treated PC3 cells. B. qPCR results showing foldchange expression of anti-apoptotic markers in Mb treated samples compared to untreated
sample in PC3 cells. GAPDH was used as a control and experimental genes were compared
to GAPDH as a baseline. Fold-change values were calculated by comparing untreated and
treated samples following the D-DCt method. Error bars on qPCR results represent standard
deviation of the mean. A single asterisk (*) represents samples that were p<0.05, a double
asterisk (**) represents samples that were p<0.005, and a triple asterisk (***) represents
samples that were p<0.0005.

150

Analysis of anti-apoptotic markers post-Mb treatments in DU145 cells
In contrast to the expression of cell cycle inhibitors observed previously, the
expression of anti-apoptotic genes in DU145 cells demonstrated the highest level of
variability across samples. As observed in PCR analyses (Figure 4-13 A), the lowest
concentration of Mb (100pM ) increased the expression of all anti-apoptotic markers with
the exception of Bcl-XL which remained unchanged. However, increasing the
concentration of Mb down-regulated the expression of all markers. Interestingly and
comparable to the results for cell cycle inhibitors in DU145 cells, the concentration of
100nM Mb up-regulated the expression of Bcl2-L10 and Bcl-XL. Similar results were
observed after quantification with qPCR analysis (Figure 4-13 B). Low concentrations of
Mb increased the expression of anti-apoptotic markers while higher concentrations of Mb
resulted in decreased expression. None of the responses appeared to occur in a dosagedependent manner. These results, along with those observed in LnCap and PC3 cells,
appear to indicate a delicate Mb dose threshold, where amounts of AR activation can turn
over the expression of these markers. Additionally, there appears to be a subtle balance for
the amount of AR activation and DAX-1 expression in these cells that induce beneficial
changes in the expression of these markers.
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Figure 4-13. Expression of anti-apoptotic markers post-Mb treatments in DU145 cells.
A. Agarose gel electrophoresis of PCR samples comparing the expression of anti-apoptotic
markers in untreated (1%ETOH) and Mb treated DU145 cells. B. qPCR results showing
fold-change expression of anti-apoptotic markers in Mb treated samples compared to
untreated sample in DU145 cells. GAPDH was used as a control and experimental genes
were compared to GAPDH as a baseline. Fold-change values were calculated by comparing
untreated and treated samples following the D-DCt method. Error bars on qPCR results
represent standard deviation of the mean. A single asterisk (*) represents samples that were
p<0.05, a double asterisk (**) represents samples that were p<0.005, and a triple asterisk
(***) represents samples that were p<0.0005.
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Analysis of anti-apoptotic markers post-Mb treatments in LCR1 cells
The expression of some anti-apoptotic markers in LCR1 cells was comparable to
that observed for LnCap cells in PCR analyses. The expression of Bcl2-L10 was upregulated at low concentrations of Mb and decreased at higher concentrations of Mb,
similar to what was observed in LnCap cells (Figure 4-14 A). No expression of Bcl2-A1
was observed in treated and untreated samples. However, as opposed to the changes
observed in LnCap cells, the expression of Bcl-2 and Bcl2-XL was up-regulated in Mb
treated samples. A clearer change in the expression of anti-apoptotic markers was observed
in the quantified samples by qPCR analyses (Figure 4-14 B). The expression of all antiapoptotic markers was significantly increased at low concentrations of Mb. Interestingly,
higher Mb concentrations did not appear to affect the expression of these markers. The
overall trend observed in LCR1 cells was opposite to that observed in LnCap cells. These
results confirm that DAX-1 appears to have repressive properties in some of these markers,
and there is a subtle Mb dose threshold that appears to change the effects of AR activation
in these cells.
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Figure 4-14. Expression of anti-apoptotic markers post-Mb treatments in LCR1 cells.
A. Agarose gel electrophoresis of PCR samples comparing the expression of anti-apoptotic
markers in untreated (1%ETOH) and Mb treated LCR1 cells. B. qPCR results showing
fold-change expression of anti-apoptotic markers in Mb treated samples compared to
untreated sample in LCR1 cells. GAPDH was used as a control and experimental genes
were compared to GAPDH as a baseline. Fold-change values were calculated by comparing
untreated and treated samples following the D-DCt method. Error bars on qPCR results
represent standard deviation of the mean. A single asterisk (*) represents samples that were
p<0.05, a double asterisk (**) represents samples that were p<0.005, and a triple asterisk
(***) represents samples that were p<0.0005.
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Analysis of anti-apoptotic markers in DAX-1+ PC3 cells
The expression of anti-apoptotic markers was significantly downregulated in all
DAX-1 positive samples. These results support previous findings in Dr. TzagarakisFoster’s laboratory where transient transfections of DAX-1 in DAX-1 negative breast
cancer cells was sufficient to down-regulate the expression of these anti-apoptotic markers.
Here we show the same effect in the prostate cancer cell line PC3. The expression of all
anti-apoptotic markers was decreased as verified by standard PCR analysis (Figure 4-15 A).
The expression of Bcl-2, Bcl2-XL, and Bcl2-L10 was also down-regulated as determined
by qPCR analysis (Figure 4-15 B). In the case of the marker Bcl2-A1, introduction of the
pcDNA plasmid significantly increased its expression, as shown in the empty vector
sample. These results indicate that the minimal increase observed in qPCR for this marker
was likely due to the plasmid backbone and not specifically due to DAX-1 expression.
Therefore, the expression of Bcl2-A1 can be assumed to also have been down-regulated in
the presence of DAX-1 as observed in PCR analysis. Finally, the protein expression of Bcl2 and Bcl2-L10 was again down-regulated when verified with western blot analyses (Figure
4-16). The expression of GAPDH did not change for any of the aforementioned studies
and was used as a positive control. Moreover, GAPDH was used as a baseline when
comparing experimental genes.
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Figure 4-15. mRNA expression of anti-apoptotic markers in DAX-1+ PC3 cells. A.
Agarose gel electrophoresis of PCR samples comparing the expression of anti-apoptotic
markers in untreated (Lafectine) and pcDNA DAX-1 transfection of 3ug plasmid in PC3
cells. B. qPCR results showing fold-change expression of anti-apoptotic markers in UT
samples compared to an empty vector and to DAX-1 + PC3 cells. GAPDH was used as a
control and experimental genes were compared to GAPDH as a baseline. Fold-change
values were calculated by comparing untreated and treated samples following the D-DCt
method. Error bars on qPCR results represent standard deviation of the mean. A single
asterisk (*) represents samples that were p<0.05, a double asterisk (**) represents samples
that were p<0.005, and a triple asterisk (***) represents samples that were p<0.0005.
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Figure 4-16. Protein expression of anti-apoptotic markers in DAX-1+ PC3 cells.
Western Blot analysis comparing protein expression of anti-apoptotic markers in UT
(Lafectine) and DAX-1 + PC3 cells. GAPDH was used as a positive control.
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Analysis of apoptosis using Annexin V/PI staining in LnCap, LCR1, and DAX-1+ PC3 cells
Annexin V and PI staining analysis was used to verify whether the aforementioned
changes in the expression of cell cycle inhibitors and anti-apoptotic markers were sufficient
to affect the apoptotic rates of these cells. In LnCap cells treated with Mb, an increase in
the Annexin staining was observed (Figure 4-17 A). The contour diagrams for Flow
Cytometry analyses show the increase in the percentage of cells in both the lower right
quadrant (early-apoptotic cells) and the upper right quadrant (late-apoptotic cells).
Moreover, the percentage of cells that were solely stained with PI was decreased in Mb
treated samples. This result indicates that most of the cells in the population were preapoptotic cells or cells undergoing apoptosis, as observed with the increase of Annexin V
staining. The dose response curve in Figure 4-17 B illustrates these results and demonstrate
that an increase in the percentage of cells is observed for those stained with Annexin V/ PI
and Annexin V alone.
In LCR1 cells, the results of the Annexin V/PI staining were completely opposite to
those observed in LnCap cells. As observed in the contour diagrams (Figure 4-18 A) and
the dose response curve (Figure 4-18 B), the percentage of cells stained with Annexin V/ PI
and Annexin V alone was approximately the same across all samples. There was no
induction of apoptosis across treatments when DAX-1 was not present. These results show
that DAX-1 is a key element for inducing apoptosis in these cells.
Finally, results from DAX-1 transfections into PC3 cells showed comparable
results. As shown in Figure 4-19, there was an increase in the percentage of apoptotic cells
in the population when DAX-1 was present.
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Figure 4-17. Analysis of apoptosis using Annexin/PI staining post-Mb treatments in
LnCap cells. A. Contour diagram of FITC-Annexin V/PI flow cytometry of LnCap cells in
UT and Mb treatments cells. B. Dose response curve quantifying the right-hand quadrants
from each cell flow cytometry sample to give value to the number of apoptotic cells with or
without treatment.
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Figure 4-18. Analysis of apoptosis using Annexin/PI staining post-Mb treatments in
LCR1 cells. A. Contour diagram of FITC-Annexin V/PI flow cytometry of LCR1 cells in
UT and Mb treatments cells. B. Dose response curve quantifying the right-hand quadrants
from each cell flow cytometry sample to give value to the number of apoptotic cells with or
without treatment.
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Figure 4-19. Analysis of apoptosis using Annexin/PI staining in PC3 and PC3+DAX-1
cells. A. Contour diagram of FITC-Annexin V/PI flow cytometry of PC3 cells in UT
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Discussion
Because a hallmark of cancer progression is the ability of cancer cells to avoid
apoptosis, the study of all the markers that determine whether a cell will undergo apoptosis
is crucial. This chapter evaluated the effects that AR activation and DAX-1 expression have
on influencing markers that regulate programmed cell death.

Modulation of cell cycle inhibitors by AR and DAX-1 in prostate cancer cells
Cell cycle inhibitors have been shown to affect apoptosis in an indirect manner by
inducing cell cycle arrest. While these markers seem to have both apoptotic and antiapoptotic effects, their hyper-activation or dysregulation can lead to improper CDK
activity. This in turn can lead to conflicting signals for cell division. Moreover, cell cycle
inhibitors might be able to sensitize cells to apoptosis in cells that receive conflicting
growth signals. In LnCap cells, low concentrations of Mb increased the expression of cell
cycle inhibitors, while higher concentrations decreased their expression. Comparably, in
PC3 cells that have negligible amounts of AR, all cell cycle inhibitors were up-regulated in
a dosage-dependent manner. These results are parallel to the effects observed in LnCap
cells under low Mb concentrations. Because less AR protein is available to affect downstream targets in PC3 cells, higher concentrations of Mb were needed to exhibit the same
effects observed at low Mb concentrations in LnCap cells. These results seem to indicate a
beneficial response to moderate amounts of AR activation. As previously mentioned, the
beneficial outcomes observed during AR activation might be indicative of the detrimental
effects after ADT in specific patients. These results could provide evidence of how
intermittent androgen deprivation could be more beneficial than ADT, depending on the
patient.
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In LCR1 cells, no up-regulation of cell cycle inhibitors was observed at any
concentration as seen in LnCap cells. However, there was still down-regulation of cell
cycle inhibitors at higher Mb concentrations. The lack of up-regulation observed at low Mb
concentrations might be indicative of the central role of DAX-1. Because DAX-1 is not
present in these cells, there was no direct or indirect up-regulation of these markers.
Moreover, the results observed in DAX-1 transfections into PC3 cells indicate that all cell
cycle inhibitors with the exception of p16 were up-regulated when DAX-1 is present. These
results showed that DAX-1 is sufficient to induce the expression of these markers. Whether
DAX-1 has a direct or indirect regulation on the expression of these markers remains
unknown. However, because of its repressive properties, it is expected that DAX-1 acts as a
negative regulator of a marker that represses the expression of cell cycle inhibitors.
Therefore, it is anticipated that DAX-1 regulates the expression of cell cycle inhibitors
indirectly.

Modulation of anti-apoptotic markers by AR and DAX-1 in prostate cancer cells
As previously mentioned, there are several mechanisms within the cell that
converge toward apoptosis. While the mechanism by which the Bcl-2 family inhibits
apoptosis is poorly understood, the role of Bcl-2 family members as anti-apoptotic markers
is evident. In the androgen-sensitive cell line LnCap, all the anti-apoptotic markers were
observed to decrease in a dosage-dependent manner after Mb treatments. In PC3 and
DU145 cells that express only negligible amounts of AR, results were more variable. In
PC3 cells, low Mb concentrations and the highest concentration of 1µM decreased the
expression of Bcl-2 and Bcl2-A1. Medium to high Mb concentrations seemed to increase
the expression of these markers. In contrast to the observed result in LnCap cells, the
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expression of Bcl2-L10 and Bcl2-XL was up-regulated in a dosage-dependent manner.
Similarly, in DU145 cells, low Mb concentrations up-regulated the expression of all antiapoptotic markers. Higher Mb concentrations down-regulated their expression. These
results provide further evidence regarding the sensitive threshold by which AR affects the
expression of these markers.
In LCR1 cells, some of the results were similar to those observed in LnCap cells in
PCR analysis. However, qPCR analysis presented more discernable results. While the
expression of all the anti-apoptotic markers was up-regulated at low Mb concentrations,
there was no change in their expression at high Mb concentrations. Moreover, transient
transfections of DAX-1 into PC3 cells provided evidence that DAX-1 down-regulates the
expression of all of these anti-apoptotic markers. These results support the previous
findings in Dr. Tzagarakis-Foster’s Laboratory, where DAX-1 transfections into DAX-1
negative breast cancer cells were sufficient to down-regulate the expression of these antiapoptotic markers. Here we demonstrate that the same outcome can be observed in prostate
cancer cells. Collectively, these results further indicate the intricate threshold by which AR
activation will have beneficial effects on PCa cancer cells and the repressive actions of
DAX-1 on decreasing the expression of anti-apoptotic markers.

DAX-1 and AR regulation of apoptotic rates in prostate cancer cells
Annexin V and PI staining analyses were performed in order to analyze whether the
previously mentioned changes in anti-apoptotic markers and cell cycle inhibitors impacted
the apoptotic rates in these prostate cancer cells. As previously discussed, the apoptotic
index in LnCap cells was increased in Mb treated samples. In contrast, the apoptotic index
in LCR1 cells did not change across samples. No induction of apoptosis was perceived in
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LCR1 cells, in which DAX-1 is not available. Finally, the apoptotic index was also
increased in DAX-1 transfected cells. These results suggest that DAX-1 has a central role
in influencing apoptosis, most likely by influencing the aforementioned markers.
Throughout this chapter, the role of AR activation and DAX-1 expression on the
regulation of cell cycle inhibitors, anti-apoptotic markers, and apoptotic rates was analyzed.
The previously discussed findings suggest an indirect effect of cell cycle inhibitors on
influencing apoptosis. Their hyper-activation or dysregulation can lead to improper CDK
activity, which can be the cause of why cell cycle inhibitors induce conflicting signals for
cell division. While cell cycle inhibitors are not part of the apoptotic machinery, the
previous findings could indicate that they may function to sensitize cells to apoptosis in
cells that receive conflicting growth signals. Moreover, the interplay between cell cycle
regulators and apoptotic elements influences the ultimate fate of a cell. Signals that affect
the expression of anti-apoptotic markers could be one of the main routes by which cancer
cells avoid apoptosis. The regulation of these markers and their repressors, such as DAX-1,
is crucial for understanding the progression of cancer cells. Understanding the link between
the cell cycle and apoptosis is essential in the search for new therapeutic strategies to
combat cancer. Furthermore, the previous findings suggest some of the beneficial effects of
AR activation on influencing apoptosis in prostate cancer cells. These results can provide
further evidence of how intermittent androgen deprivation therapies can be more beneficial
for certain patients. Moreover, these studies illustrate the complexity of cancer biology and
reveal the specificity that molecular signals have on influencing the progression of a cancer.
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Chapter 5
Regulation of metastasis by AR and DAX-1 in prostate cancer cells
Introduction
The ability of cancer cells to metastasize is the principal event that ultimately leads
to patient death, yet its molecular basis is not well understood. It is known that the potential
of cancer cells to metastasize depends on a multi-step biological process driven by the
acquisition of genetic and epigenetic alterations within tumor cells. In addition,
extracellular signaling with non-neoplastic stromal cells provides metastatic cells with traits
needed to produce macroscopic metastases. Further research is needed to investigate the
biological and molecular changes that allow metastasis of cancer cells, and such molecular
targets can provide putative therapeutic targeting.
While surgical intervention and adjuvant therapy can cure confined first grade
tumors, metastasis is incurable at large due to its systemic nature and resistance to existing
therapeutics. More than 90% of cancer deaths can be attributed to metastases and not to the
primary tumors where the malignant lesions originated [138]. There are complex cellbiological events that allow metastases of carcinoma cells. These biological events include
the ability of primary tumors to locally invade their surrounding extracellular matrix (ECM)
and stromal cell layers, to intravasate into blood vessels, to survive transport through
vasculature, to arrest at distant organs, to extravasate into parenchyma of tissues, and to
reinstate into detectable neoplastic growths [139]. These events are orchestrated by the
molecular mechanisms operating within cancer cells. Deregulation of intrinsic and extrinsic
signaling cascades allows primary tumor cells to become life-threatening malignancies. The
study of the molecular mechanisms that allow the primary tumors to locally invade their

166

surrounding ECM and stromal cell layers is the critical element that results in avoiding
metastases.

Metastatic Pathways
At the cell-biological level, individual tumor cells are able to invade the ECM
through mesenchymal invasion. They achieve mesenchymal invasion by opting for a
biological process known as epithelial-mesenchymal transition (EMT), that is critical for
aspects of normal embryonic morphogenesis. EMT involves the dissolution of tight
junctions, adherens junctions, and a loss of cell polarity, ultimately leading to cell
disassociation within epithelial cell sheets into individual cells with mesenchymal
attributes, including invasiveness [140]. EMT is coordinated by multiple transcription
factors, including Slug, Twist, and Snail among others, that allow cells to enter a
mesenchymal state by suppressing expression of epithelial markers and inducing the
expression of markers associated with the mesenchymal state [141]. The transforming
growth factor β (TGF-β) pathway in one of the most important EMT inducing pathways in
a variety of cancer cells [142]. TGF-β is able to mediate EMT induction through
transcriptional activation of Twist, Snail, Slug, and Zeb-1 [143]. Moreover, ectopic
expression of Twist has been shown to cause loss of E-cadherin-mediated cell-cell
adhesion, activation of mesenchymal markers, and induction of cell motility [144].
Similarly, ectopic expression of Slug was shown to induce vimentin, allowing for EMTassociated migration of pre-malignant epithelial cells [145]. In addition, Slug has also been
shown to repress the transcription of several polarity factors, indicating its role as a
suppressor of critical components of epithelial cell traits [146, 147].
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The Wnt signaling pathway is also part of the complex network of signaling
pathways that govern EMT tumor morphogenesis [148]. In the absence of a Wnt ligand, βcatenin is degraded in the cell by a destruction complex consisting of Axin, Adenomatous
polyposis coli (APC), glycogen synthase kinase-3β (GSK-3 β), and casein kinase (CK-1).
CK-1 and GSK-3 β phosphorylate β-catenin tagging it for ubiquitination and proteosomal
degradation. Upon Wnt ligand binding, inactivation of GSK-3 β occurs, which stabilizes
cytosolic β-catenin and promotes its nuclear translocation. In the nucleus, β-catenin acts as
a co-activator of transcription factors that belong to the T cell factor/ Lymphoid enhancerbinding factor (TCF/LEF) family [149]. The Wnt/β-catenin pathway has been associated
with induction of EMT morphogenesis [150]. Inhibition of the Wnt/β-catenin signaling
pathway has been associated with increased expression of epithelial markers and decreased
expression of mesenchymal markers, such as Slug and Twist [151]. Moreover, knockdown
of β-catenin has been associated with the reversal of EMT through elevated expression of
E-cadherin and decreased expression of the mesenchymal markers Vimentin, MMP-2, and
N-cadherin [152]. Similarly, studies have shown that β-catenin is able to induce EMT
through induction of LEF-1 [153]. Dickkopf1 (DKK1) is a secreted inhibitor of the Wnt
signaling pathway and has emerged as a key regulator molecule for vertebrate embryonic
development and several human diseases, including cancer [154]. As a negative regulator
of Wnt, DKK1 could provide a prospective therapeutic marker for cancer metastatic
behavior.
DKK1 has been thoroughly studied for its role in influencing the metastatic
behavior of multiple cancers. A wide range of DKK1 expression has been reported at
various stages of tumorigenesis in multiple cancers, including prostate, breast, colorectal,
lung, esophageal, and multiple myeloma [155, 156]. Prostate cancers have been shown to
168

express lower levels of DKK1 when compared to those of normal prostate tissue.
Moreover, PCa bone metastases typically exhibit excess bone formation or osteoblastic
lesions [157]. Studies have shown that PCa cells induce osteoblastic metastases through
activation of Wnt signaling and that Wnt signaling induces the survival of pluripotent
mesenchymal progenitor cells [157, 158]. However, DKK1 has been shown to stimulate
prostate cancer growth and metastasis in cells injected to athymic mice and to decrease
osteoblastic activity via the Wnt canonical pathway [159]. In addition, DKK1
concentrations from patients with breast cancer and bone metastases are higher for women
in remission, patients with metastases at non-bone sites, and healthy women [160].
Overexpression of DKK1 in prostate cancer cell models has been shown to change a mixed
osteolytic-osteoblastic phenotype to a sole osteolytic phenotype [157]. These results
suggest that DKK1 may act as a molecular switch allowing osteolytic metastases to become
osteoblastic in advanced metastatic cancers. Moreover, it is possible that DKK1 promotes
different outcomes depending on the location and the components of the microenvironment
[161]. Thus, DKK1 appears to have dual roles on influencing the metastatic behavior of
cancer cells. The role of DKK1 as a tumor and metastatic promoter continues to be an
active area of research.
Bone metastases are a frequent complication in patients with advance stages of
cancer. These bone metastases are generally classified as osteolytic or osteoblastic,
characterized by the destruction of normal bone or the uncontrolled deposition of new bone
respectively. Many patients with metastases can have both osteoblastic and osteolytic
lesions. These metastases result in the dysregulation of the normal bone remodeling
process, which is lethal for patients [162]. The bone-specific transcriptional regulator
RUNX2 is abnormally expressed in highly metastatic prostate cancer cells. Studies have
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shown that RUNX2 facilitates tumor growth and increases the expression of metastasisrelated genes, like MMP9, MMP13, VEGF, and Osteopontin [163]. Moreover, RUNX2
silencing has been associated with a decreased invasion of prostate cancer cells and
decreased osteoclastogenic properties [163]. The aforementioned metastatic pathways are
summarized in Figure 5-1.
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Figure 5-1. Metastatic pathways. The TGFβ targets Slug and Twist, which repress the
expression of E-cadherin and promote EMT, invasion, and metastasis. Slug and Twist can
also up-regulate β-catenin expression through repression of E-cadherin. Another TGFβ
target RUNX2 acts as a powerful metastatic inducer and osteoblastic promoter. The Wnt
signaling pathway targets β-catenin, which is able to up-regulate the expression of Slug and
Twist as well as induce Vimentin, a marker for E-cadherin repression and metastatic
promoter. Dkk1 acts as a Wnt signaling antagonist and can induce osteoclastogenesis and
prevent osteoblastogenesis depending on its microenvironment.
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Regulation of metastasis by AR
PCa patient prognosis is predominantly determined by the presence or absence of
metastases. The development of metastases to the bone are highly common in the advanced
stages of prostate cancer. However, the molecular mechanisms behind the metastatic
pathways in prostate cancer have not been completely explored. Point mutations in the AR
gene have been identified in metastatic cells. Functional studies of mutant androgen
receptors demonstrated that mutant ARs can be activated by progesterone and estrogen
[164]. This is potentially correlated with the progression of prostate cancer in androgenindependent prostate cancers. However, some studies have uncovered the positive effect
AR can have in androgen-independent prostate cancer cells [165, 166]. Another study
demonstrated the role non-mutant AR has in inhibiting epithelial-mesenchymal transition,
migration, and invasion in prostate cancer cells [166]. Certain markers, like RUNX2, are
highly expressed in prostate tumors and cells that metastasize to the bone environment
[167]. AR has been shown to inhibit RUNX2 in osteoblasts and prostate cancer cells [165].
In addition, other metastatic markers like Twist have been shown to be
overexpressed in prostate cancer tissues and positively correlated with Gleason score and
metastasis [168]. However, the role AR has in regulating Twist has not been completely
explored. Our studies investigating the regulation of several markers involved in metastasis
through AR activation with a non-aromatizable androgen will provide novel data showing
the role AR has in advanced prostate cancers and CRPC. Furthermore, the role of DAX-1
in regulating markers involved in different metastatic pathways has never been explored in
prostate cancer models. Our studies will provide a putative role of DAX-1 in the
progression of advanced prostate cancer metastases. As illustrated in Figure 5-2, we expect
DAX-1 to have repressive properties of metastatic markers.
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Figure 5-2. Putative regulation of metastatic markers by DAX-1 in prostate cancer
cells. As a transcriptional repressor, DAX-1 potentially down-regulates the expression
metastatic markers.
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Materials and Methods
Reagents
Metribolone (Mb) was used for cell treatments using the same protocol described in
Chapter 2.

RNA extraction and cDNA synthesis
RNA extraction and cDNA synthesis were performed as described in Chapter 2
using the RNeasy Mini Kit (Qiagen, Valencia, CA) as per the manufacturer's instruction,
with the optional RNase-Free DNAse (Qiagen) step added to remove genomic DNA
contamination. The QuantiTect Reverse Transcription Kit (Qiagen) was used to synthesize
cDNA from the isolated RNA according to manufacturer's instructions.

PCR
cDNA synthetized from extracted mRNA was used as a template for standard PCR
and PCR reaction samples were prepared as described in Chapter 2. Primers used for
proliferation targets are summarized in Table 3-1. Following PCR, samples were
electrophoresed through a 2% 1X TAE agarose gel (Thermo Scientific, Wilmington, DE)
containing EtBr (Biorad, Hercules, CA) at 0.5 µg/mL final concentration, usually about 2µl
per 100mL gel. PCR products were visualized under ultraviolet light exposure using the
BioRad GelDoc System (BioRad, Hercules, CA). Images are representative of five
independent experiments.

Quantitative PCR (qPCR)
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cDNA synthetized from extracted mRNA was used as a template for qPCR. qPCR
reactions were performed as described in Chapter 2. Primers used for metastatic targets are
summarized in Table 5-1. GAPDH housekeeping gene was used as control and
experimental genes were compared to GAPDH as a baseline. Fold-change values were
calculated by comparing untreated and treated samples following the delta-delta Ct method.
Error bars on qPCR results represent standard deviation of the mean. Images are
representative of five independent experiments.

Table 5-1. List of Primers used for standard PCR and two-step amplification qPCR.
Gene
Name
Housekeeping
gene

GAPDH

Target

DAX-1
DKK1
b-catenin

Metastatic
genes

RUNX2
Slug
Twist

Forward Primer 5’-3’

Reverse Primer 5’-3’

CCATCACCATCTTCCA
GGAGCG
GGGTAAAGAGGCGCT
ACCAG
AACGCTGCATGCGTCA
CGCTA
TTAAACTCCTGCACCC
ACCAT
AACTCAAGTCCCCCGC
CTCCC
AGCAGTTGCACTGTGA
TGCC
GGAGTCCGCAGTCTTA
CGAG

AGAGATGATGACCCTT
TTGGC
GCTTGATTTGTGCTCG
TGGG
TCCTGAGGCACAGTCT
GATGACCG
AGGGCAAGGTTTCGA
ATCAA
GCCACGGGCAGGGTCT
TGTT
ACACAGCAGCCAGATT
CCTC
TCTGGAGGACCTGGTA
GAGG

Annealing
Temperature
58ºC
56ºC
53ºC
48ºC
50ºC
53ºC
57ºC

Protein Isolation
Whole cell protein lysate was collected as described in Chapter 2 following 48-hour
treatments.
Western Blot
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Western blots were performed using the Xcell II Blot Module (Invitrogen, Carlsbad,
CA) according to the NuPAGE Novex Bis-Tris Protocol (Invitrogen, Carlsbad, CA) as
described in Chapter 2. Antibodies used for Western Blot are summarized in Table 5-2.
Images are representative of three independent experiments.

Table 5-2. Antibodies used for Western Blot
Protein
GAPDH
DAX-1
RUNX2
Slug
Twist

Species
Rabbit (polyclonal)
Mouse (monoclonal)
Goat (monoclonal)
Rabbit (polyclonal)
Rabbit (polyclonal)

Company
Cell Signaling, Danvers, MA
Active Motif, Carlsbad, CA
RD systems, Minneapolis, MN
GeneTex, Irvine, CA
GeneTex, Irvine, CA

CRISPR/Cas9- mediated DAX-1 knockout in LnCaP cells
The stable CRISPR/Cas9-mediated DAX-1 KO cell line ‘LCR1’ was used for
experiments evaluating the regulation of AR and DAX-1 on metastatic markers.

DAX-1 knock-in into PC3 cells using pcDNA3.1-DAX-1 construct
Transient transfection assays to knock-in DAX-1 expression in PC3 cells were
performed as mentioned in Chapter 3.

Scratch/Wound Healing Assay
A convenient and inexpensive method for cell migration analysis in vitro involves a
scratch and heal assay. As shown in Figure 5-3, the main step of a scratch and heal assay
involves the creation of a “scratch” in a cell monolayer and capturing images at the
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beginning and at intervals during the migration of the cells to close the scratch. The images
can then be analyzed and compared to quantify the migration rate of the cells. We were
able to analyze the migration of individual cells in the leading edge of the scratch,
comparing their mean distance traveled and their longest distance traveled. Afterwards, we
compared the mean distance traveled and longest distance traveled across Mb treatments in
LnCap and LCR1 cells. We also analyzed the mean distance traveled and longest distance
traveled in PC3 and PC3 DAX+ cells. These analyses provided a glimpse into the role AR
and DAX-1 have in regulating the migration rates of prostate cancer cells.
Cells were cultured to confluence or near 90% confluence in a 4 well slide.
Treatments with Mb were done 24-hours prior to scratch. Using a sterile insulin syringe
with 29G needle, three separate wounds were scratched through the cells. Cells were
analyzed for 96 hours, taking a picture of cell progression every hour. Photographs were
taken using the Zeiss A1 AxioObserver fluorescence microscope (Carl Zeiss Microscopy,
LLC, Thornwood, NY) and image acquisition and analysis was performed using
AxioVision software. Image J was used to analyze mean of distance traveled and longest
distance traveled for the population of cells adjacent to the scratch as shown in Figure 5-4.
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Figure 5-3. Scratch and heal Assay. The main step of a scratch and heal assay involves
the creation of a “scratch” in a cell monolayer and capturing images at the beginning and at
intervals during the migration of the cells to close the scratch.
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Figure 5-4. Image J selection of cells adjacent to scratch. Image J is used to individually
select cells at the leading edge of the scratch. The distance traveled for each cell is analyzed
and measured in pixels and quantified.
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Statistical Analysis
Statistical significance was calculated using the two-tailed t-test formula built
into Microsoft Excel. Data was found to be statistically significant if p< 0.05.
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Results
Analysis of metastatic markers post-Mb treatments in LnCap cells
The expression of the Wnt inhibitor DKK1 was variable across all cell lines. In
LnCap cells, little to no expression of DKK1 was observed in the agarose gel
electrophoresis of PCR samples (Figure 5-5 A). Conversely, b-catenin expression was
detectable and expression levels of b-catenin increased at low Mb concentrations and
decreased at high Mb concentrations. The expression of Twist was decreased in all Mb
treated samples and was observed to decrease in a dosage-dependent manner. Expression of
Slug was close to undetectable in UT samples, but was up-regulated across Mb treated
samples. Finally, expression of RUNX2 was decreased in Mb treated samples. qPCR
analyses showed clearer results as shown in Figure 5-5 B. DKK1 expression was downregulated in Mb treated samples. Conversely, expression of b-catenin was up-regulated at
low Mb concentrations and was decreased at high Mb concentrations. The expression of
Twist was down-regulated in a dosage-dependent manner. In contrast, expression of Slug
was increased in a dosage-dependent manner. Finally, expression of RUNX2 was downregulated in a dosage-dependent manner. The expression of GAPDH did not change across
treatments and was used as a positive control and as a baseline to compare treated samples.
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Figure 5-5. Expression of metastatic markers post-Mb treatments in LnCap cells. A.
Agarose gel electrophoresis of PCR samples comparing the expression of metastatic
markers in untreated (1%ETOH) and Mb treated LnCap cells. B. qPCR results showing
fold-change expression of metastatic markers in Mb treated samples compared to untreated
sample in LnCap cells. GAPDH was used as a control and experimental genes were
compared to GAPDH as a baseline. Fold-change values were calculated by comparing
untreated and treated samples following the D-DCt method. Error bars on qPCR results
represent standard deviation of the mean. A single asterisk (*) represents samples that were
p<0.05, a double asterisk (**) represents samples that were p<0.005, and a triple asterisk
(***) represents samples that were p<0.0005.
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Analysis of metastatic markers post-Mb treatments in PC3 cells
In contrast to LnCap cells, high expression of DKK1 was observed in PC3 cells, as
verified by agarose gel electrophoresis of PCR samples (Figure 5-6 A). DKK1 expression
was up-regulated in Mb treated samples in a dosage-dependent manner. Conversely, bcatenin expression was not detected. As seen in LnCap cells, the expression of Twist was
down-regulated in Mb treated samples in a dosage-dependent manner. In contrast to LnCap
cells, expression of Slug was detected in UT samples and was observed to decrease in Mb
treated samples. Finally, expression of RUNX2 was up-regulated at very low Mb
concentrations, but down-regulated at medium to high Mb concentrations. Similar results
were observed when quantified with qPCR analysis (Figure 5-6 B). The expression of
DKK1 was up-regulated in a semi dosage-dependent manner. Conversely, expression of bcatenin was down-regulated in Mb treated samples. The expression of Twist decreased in
Mb treated samples, although results were not significant. Moreover, expression of Slug
was decreased in Mb treated samples. Finally, expression of RUNX2 was decreased
significantly only at high Mb concentrations. GAPDH expression was stable across
treatments and was used as a positive control. In addition, GAPDH was used as a baseline
when comparing treated samples.
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Figure 5-6. Expression of metastatic markers post-Mb treatments in PC3 cells. A.
Agarose gel electrophoresis of PCR samples comparing the expression of metastatic
markers in untreated (1%ETOH) and Mb treated PC3 cells. B. qPCR results showing foldchange expression of metastatic markers in Mb treated samples compared to untreated
sample in PCr cells. GAPDH was used as a control and experimental genes were compared
to GAPDH as a baseline. Fold-change values were calculated by comparing untreated and
treated samples following the D-DCt method. Error bars on qPCR results represent standard
deviation of the mean. A single asterisk (*) represents samples that were p<0.05, a double
asterisk (**) represents samples that were p<0.005, and a triple asterisk (***) represents
samples that were p<0.0005.
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Analysis of metastatic markers post-Mb treatments in DU145 cells
Similar to the results observed in PC3 cells, DU145 cells do express DKK1, as
verified by standard PCR analyses (Figure 5-7 A). Conversely, expression of b-catenin was
not detected. In contrast to LnCap and PC3 cells, expression of Twist was also not detected.
Moreover, expression of Slug seemed to increase at the lowest Mb concentration, decrease
at medium Mb concentrations, increase at 100nM Mb concentration, and decrease at the
highest Mb concentration of 1µM. Finally, the expression of RUNX2 appeared to remain
unchanged across Mb treatments and decrease significantly at the highest Mb concentration
of 1µM. Similar results were observed in qPCR analyses (Figure 5-7 B). The expression of
DKK1 was up-regulated in Mb treated samples. Significant down-regulation of b-catenin
was only observed at high Mb concentrations. Similarly, significant decrease in the
expression of Twist was observed at high Mb concentrations. Moreover, the expression of
Slug appeared to decrease at medium Mb concentrations, remain unchanged at the lowest
Mb concentration of Mb and 100nM concentration, and decrease significantly at the highest
Mb concentration (1µM). Finally, the expression of RUNX2 was significantly downregulated in a dosage-dependent manner. The expression of GAPDH did not change across
treatments, was used as a positive control, and was used as a baseline when comparing
treatments across samples.
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Figure 5-7. Expression of metastatic markers post-Mb treatments in DU145 cells. A.
Agarose gel electrophoresis of PCR samples comparing the expression of metastatic
markers in untreated (1%ETOH) and Mb treated DU145 cells. B. qPCR results showing
fold-change expression of metastatic markers in Mb treated samples compared to untreated
sample in DU145 cells. GAPDH was used as a control and experimental genes were
compared to GAPDH as a baseline. Fold-change values were calculated by comparing
untreated and treated samples following the D-DCt method. Error bars on qPCR results
represent standard deviation of the mean. A single asterisk (*) represents samples that were
p<0.05, a double asterisk (**) represents samples that were p<0.005, and a triple asterisk
(***) represents samples that were p<0.0005.
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Analysis of metastatic markers post-Mb treatments in LCR1 cells
The expression of all metastatic markers was increased in DAX-1 negative LCR1
cells as shown in Figure 5-8 A. Standard PCR analysis demonstrated the expression of
DKK1 was detected when DAX-1 was not present. Expression of b-catenin was higher than
expression in LnCap cells and increased in Mb treated samples. Moreover, the expression
of Twist was higher than expression in LnCap cells and increased in Mb treated samples. In
contrast to LnCap cells, expression of Slug was detected in UT samples and had a
significant increase in expression in Mb treated samples. Finally, the expression of RUNX2
was increased in Mb treated samples. Similar results were observed after quantification
with qPCR analysis (Figure 5-8 B). Expression of DKK1 was significantly lower at the
lowest and highest Mb concentrations. In addition, expression of b-catenin was upregulated in a semi dosage-dependent manner in Mb treatments. Similarly, the expression
of Twist was up-regulated in a semi dosage-dependent manner in Mb treated samples.
Moreover, the expression of Slug was up-regulated in Mb treated samples. Finally,
expression of RUNX2 increased in Mb treated samples in a semi dosage-dependent
manner. GAPDH expression did not change across samples and was used as a positive
control. GAPDH was also used as a baseline when comparing treated samples.
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Figure 5-8. Expression of metastatic markers post-Mb treatments in LCR1 cells. A.
Agarose gel electrophoresis of PCR samples comparing the expression of metastatic
markers in untreated (1%ETOH) and Mb treated LCR1 cells. B. qPCR results showing
fold-change expression of metastatic markers in Mb treated samples compared to untreated
sample in LCR1 cells. GAPDH was used as a control and experimental genes were
compared to GAPDH as a baseline. Fold-change values were calculated by comparing
untreated and treated samples following the D-DCt method. Error bars on qPCR results
represent standard deviation of the mean. A single asterisk (*) represents samples that were
p<0.05, a double asterisk (**) represents samples that were p<0.005, and a triple asterisk
(***) represents samples that were p<0.0005.
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Analysis of metastatic markers in DAX-1+ PC3 cells
The expression of most metastatic markers was decreased in DAX-1 + PC3 cells as
verified by agarose gel electrophoresis of PCR samples (Figure 5-9 A). DKK1 expression
was slightly decreased in DAX-1 + samples. The expression of b-catenin was not
detectable in UT and DAX-1 + samples. Twist expression drastically decreased in DAX-1+
samples. Similarly, Slug expression significantly decreased in DAX-1+ samples. Finally,
expression of RUNX2 was significantly decreased in DAX-1+ samples. Similar results
were observed in samples quantified with qPCR analysis as shown in Figure 5-9 B. The
expression of DKK1 was decreased when DAX-1 was present. Expression of b-catenin was
decreased in samples transfected with the empty vector as well as DAX-1. Therefore, it can
be inferred that the expression of b-catenin remained unchanged across samples because
the down-regulation observed was a result of the plasmid and not a result of DAX-1
expression. The most striking change was observed in the significant down-regulation of
Twist expression in DAX-1 + cells. Moreover, expression of Slug was also down-regulated
in DAX-1+ samples. Finally, expression of RUNX2 was similarly down-regulated in DAX1 + samples.
Since the most significant down-regulation was observed in the expression of Twist,
Slug, and RUNX2, protein expression analyses were performed with Western Blot analysis
(Figure 5-10). As observed in PCR and qPCR analyses, the protein expression of these
three targets was significantly decreased in the DAX-1 + samples. GAPDH did not change
across treatments in the previously discussed experiments and was used as a positive
control. GAPDH was also used as a baseline when comparing treated samples.
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Figure 5-9. mRNA expression of metastatic markers in DAX-1+ PC3 cells. A. Agarose
gel electrophoresis of PCR samples comparing the expression of metastatic markers in
untreated (Lafectine) and pcDNA DAX-1 transfection of 3ug plasmid in PC3 cells. B.
qPCR results showing fold-change expression of metastatic markers in UT samples
compared to an empty vector and to DAX-1 + PC3 cells. GAPDH was used as a control
and experimental genes were compared to GAPDH as a baseline. Fold-change values were
calculated by comparing untreated and treated samples following the D-DCt method. Error
bars on qPCR results represent standard deviation of the mean. A single asterisk (*)
represents samples that were p<0.05, a double asterisk (**) represents samples that were
p<0.005, and a triple asterisk (***) represents samples that were p<0.0005.
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DAX-1 + PC3 cells. GAPDH was used as a positive control.
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Analysis of metastatic rates in LnCap cells post Mb treatments
Scratch and heal assays were used to analyze the metastatic rates of prostate cancer
cell lines with Mb treatments. A “scratch” was made in a monolayer of cells and
photographs were taken of the migration of cells every hour for a period of 96 hours. As
shown in Figure 5-11 A, LnCap cells invaded the scratch area, but only a few Mb
treatments showed almost complete wound closure. The cells adjacent to the scratch were
selected and their migration patterns were analyzed using Image J Software. The distance
traveled for each individual cell was recorded and the average was graphed next to the
longest distance traveled for each Mb treatment. In LnCap cells, the distance traveled
means were higher in Mb treated cells and the averages appear to increase in a dosagedependent manner (Figure 5-11 B). However, when analyzing the maximum distance
traveled for each treatment, distances were lower for Mb treated cells.

Analysis of metastatic rates in LCR1 cells post Mb treatments
In LCR1 cells, the pattern of migration observed was different than that observed in
LnCap. Cells did not appear to grow in a monolayer fashion, but in clumps and in a threedimensional manner (5-12 A). The average distance traveled was almost equal to that of
LnCap cells for untreated samples as shown in Figure 5-12 B. In addition, the average
distance traveled also increased in Mb treated samples, but in a non-discernible pattern. In
contrast to LnCap cells, the maximum distances traveled were higher for Mb treated cells
than untreated cells in LCR1 cells.
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Figure 5-12. Scratch and heal assay in Mb treated LCR1 cells. A. Scratch and heal
assay was performed to determine the effect of Mb treatments on the migration of LCR1
cells 0–96  hours. Scale bar represents 100µm. B. Bar graph representation of mean and
maximum distance (in pixels) traveled for UT (1% ETOH) and Mb treated LCR1 cells.
Distance traveled for every cell adjacent to the scratch was derived using Image J. A single
asterisk (*) represents samples that were p<0.05, a double asterisk (**) represents samples
that were p<0.005, and a triple asterisk (***) represents samples that were p<0.0005.
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Analysis of metastatic rates in DAX-1+ PC3 cells
PC3 cells grow aggressively in culture and the same pattern was observed in
untreated cells. As shown in Figure 5-13 A, PC3 cells invaded the scratch area readily and
closed the wound in 96 hours. The division rate and aggressive behavior of the cells can
also be visualized. In contrast, DAX-1+ PC3 cells didn’t exhibit the same behavior. The
cells didn’t move as aggressively and their division rate was significantly decreased. In
addition, the void created by the scratch remained the same throughout the 96 hours. As
shown in Figure 5-13 B, the average of distance traveled in PC3 cells with DAX-1 was
significantly lower the that of WT PC3 cells. Moreover, the maximum distance traveled in
PC3 cells with DAX-1 was also lower than distance traveled in WT PC3 cells lacking
endogenous DAX-1.
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Figure 5-13. Scratch and heal assay in DAX-1+ PC3 cells. A. Scratch and heal assay was
performed to determine the effect of DAX-1 on the migration of PC3 cells 0–96 hours.
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samples that were p<0.05, a double asterisk (**) represents samples that were p<0.005, and
a triple asterisk (***) represents samples that were p<0.0005.
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Discussion
The ability of cancer cells to metastasize is the crucial element that converts primary
tumor cells into life-threatening malignancies. There are multiple cell-biological events that
allow for the metastases of cancer cells, including the invasion of their surrounding ECM
and stromal cells, intravasation of blood vessels, transport through vasculature, arresting at
a distant organ, extravasation into tissues, and the ability to reinstate into new neoplastic
growths. The understanding of the molecular pathways that allow cells to invade their
surrounding ECM and to reinstate into new neoplastic growths at distant tissue organs is
critical for treatment and prevention of metastatic cancers. In order to invade their
surrounding ECM, cancer cells opt for operating EMT, a process commonly used during
embryogenesis allowing cancer cells to act as mesenchymal cells. Research investigating
the role of AR and DAX-1 regulation of genes that allow EMT of cancer cells is crucial for
treatment and prevention of advanced PCa. In addition, because bone metastases are
frequent in patients with PCa, understanding the role AR and DAX-1 plays in regulating
bone-specific transcriptional factors is necessary.

Modulation of metastatic markers by AR and DAX-1 in prostate cancer cells
There are various molecular mechanisms that allow cancer cells to acquire traits that
facilitate their ability to metastasize. A critical mechanism involves the ability of cancer
cells to operate EMT, facilitated by transcriptional factors such as Twist, Slug, and bcatenin. As a major antagonist of Wnt/b-catenin signaling, DKK1 has been studied as a
potential metastatic suppressor. However, studies have shown that DKK1 is able to enhance
tumor growth and metastasis of prostate cancer cells. Osteoblastic metastases are common
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in PCa. Incidentally, DKK1 has been shown to act as a negative modulator of
osteoblastogenesis. DKK1 therefore seems to act as a molecular switch enhancing
osteolytic metastases depending on the microenvironment. Moreover, because bone
metastases are a common complication in patients with PCa, the study of bone-specific
transcriptional regulators like RUNX2 is necessary. The studies performed throughout this
chapter aimed to analyze the role AR activation and DAX-1 expression have in the
regulation of the previously mentioned metastatic markers.
As discussed earlier, the expression of DKK1 was highly variable among cell lines.
DKK1 was negligible in LnCap cells, a cell line derived from lymph node metastasis. In
contrast, expression of DKK1 was high in PC3 and DU145 cells, derived from osteolytic
bone metastasis and brain metastasis respectively. These results are indicative of a
metastatic enhancer role of DKK1 is prostate cancer cells. In addition, the osteolytic
metastatic behavior in PC3 cells could be a cause of the negative modulatory effects DKK1
has on osteoblastogenesis. DKK1 expression decreased upon Mb treatments in the
androgen-sensitive LnCap cell line and increased in the androgen-independent cell lines
PC3 and DU145. These results indicate that AR can induce or repress the expression of
DKK1 depending on the amount of AR present and the amount of DAX-1 expression. In
LCR1 cells, where DAX-1 is no longer present, DKK1 expression was considerably higher
than in WT LnCap cells. Consistent with these results, previous research carried out in Dr.
Tzagarakis-Foster’s laboratory (data unpublished) found that DAX-1 has an effect in downregulating DKK1 expression in a different model (mouse embryonic stem cells). These
results indicate that DAX-1 acts as a potent DKK1 inhibitor in prostate cancer cells and
mouse embryonic stem cells. Whether the same effect occurs in other models remains to be
investigated.
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The expression of the EMT facilitators Twist, Slug, and b-catenin varied across cell
lines. The expression of b-catenin was highest in LnCap cells, in which DKK1 was not
present. Moreover b-catenin’s expression was negligible in PC3 and DU145 cells, in which
DKK1 is highly expressed. These results support the negative modulatory actions DKK1
has over the Wnt signaling and consequently over b-catenin’s expression. AR appeared to
act as a negative modulator of Twist in these cells. In contrast, AR acted as an inducer of
Slug expression in LnCap cells. However, in PC3 and DU145 cells, in which less AR is
expressed, the expression of Slug decreased upon Mb treatments. These results could be
indicative of a threshold of AR activation over Slug expression. Furthermore, the
expression of RUNX2 was decreased with Mb treatments across cell lines, potentially
showing that AR acts a negative modulator of some bone-specific transcriptional
regulators.
The LCR1 cell line provided a better understanding of DAX-1’s role over metastatic
markers. All metastatic markers were more highly expressed in LCR1 cells than in WT
LnCap cells and also increased in expression upon Mb treatments. Results showed that
DAX-1 is sufficient to inhibit the expression of metastatic markers. Potentially, analyzing
cancer patients for DAX-1 expression could indicate whether or not the cancer is more
likely to metastasize.
In PC3 cells transiently transfected with DAX-1, the expression of most metastatic
markers was down-regulated. The least significant down-regulation was observed in
DKK1, further demonstrating that DAX-1 and AR are together necessary to inhibit DKK1
expression. The sole expression of DAX-1 while effective, is not as strong as when it works
in conjunction with AR. The expression of b-catenin was not changed in DAX-1
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transfected cells. This result indicates that AR acts to decrease b-catenin expression
through other molecular pathways and not through DAX-1. In contrast, DAX-1 appeared to
be sufficient to down-regulate the expression of the metastatic markers Twist, Slug, and
RUNX2. All of these markers were inhibited upon DAX-1 expression, both at the mRNA
and protein levels. Altogether, these results provide evidence for the potent negative
modulatory action DAX-1 has over metastatic targets, a novel characteristic of DAX-1 not
previously addressed. As previously stated, DAX-1 expression in prostate cancer patient
biopsies could indicate the prognosis of the patient, and whether the cancer is likely to
metastasize.

DAX-1 and AR regulation of metastatic rates in prostate cancer cells
A scratch and heal assay is a simple and inexpensive method to measure migration
rates of cancer cells. In view of the expression changes of metastatic targets upon DAX-1
expression, scratch and heal assays were performed to analyze whether these changes were
sufficient to decrease metastatic rates of prostate cancer cells. The most striking results
were observed in PC3 cells transiently transfected with DAX-1. Both the average distance
traveled and maximum distance traveled were shorter in PC3 cells with DAX-1 expression.
These results provide some preliminary results about the role AR and DAX-1 have in the
migration of prostate cancer cells. DAX-1 seemed to be sufficient to decrease the migration
of PC3 cells. This could be the mechanism by which AR transfections have been shown to
decrease migration of PC3 cells observed by Huo et al. [166]. In contrast, the migration of
LnCap appears to be more complex and goes beyond simply requiring DAX-1 expression.
This could be the result of other transcriptional factors, such as the high expression of Slug

200

observed after Mb treatments. Altogether, these results open a new avenue of research for
exploring the role DAX-1 has over metastasis. Further analyses are necessary to understand
whether DAX-1 has a substantial beneficial effect over the migration of prostate cancer
cells.
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End summary

The research conducted throughout this thesis is evidence of the factors that
contribute to the intricacies of cancer biology. No biological process is ever linear, as there
is an incredible amount of cross-talk between proteins at any time within a cell. The
response to intrinsic and extrinsic factors is what mediates the outcome of a cancer cell, and
scientists’ ability to understand these processes is what paves the way for new effective
therapeutics.
The role of DAX-1 in prostate cancer has not previously been addressed. Based on
its transcriptional repressive properties in other hormone responsive cancers, such as breast
cancer, the role of DAX-1 and its co-regulatory properties with AR could provide a better
understanding of the effects of ADT and the causes of CRPC. Based on our understanding,
and according to data presented throughout this thesis, the ability of certain proteins to
accomplish beneficial outcomes in a cell is not an all or nothing response. There is a
delicate balance between the expression of gene products that achieve favorable results in
the progression of cancer cells.
Furthermore, an important factor to address is the role of estrogens in the
development and progression of PCa. Several studies have addressed the role of estrogens
and their receptors in the context of prostate cancer and concluded that they are implicated
in the development and tumor progression of PCa. In addition, there is evidence of the
diverse role different ER isoforms play in PCa progression and how there is a significant
potential for the use of ERb agonists and ERa antagonists to prevent PCa and delay the
progression of the disease [169]. Many of the beneficial aspects of AR observed throughout
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this thesis can be attributed to the use of non-aromatizable androgens, like Mb, in activating
AR. The use of non-aromatizable androgens prevented ERs to become activated in these
cells and to initiate their molecular pathways. While the use of Mb was effective in
activating AR and preventing ER activation, Mb has some affinity to PR and GR. Further
analyses of the sole role of AR in the progression of PCa and the effects of PR and GR in
the context of PCa are necessary to determine whether ADT is the most beneficial course of
treatment for patients with PCa.
There are multiple factors that contribute to the development and progression of a
cancer. It is important to analyze all contributors to the progression of a cancer rather than a
unique universal driver, such as AR in PCa. The implications of multiple molecular and
mechanistic pathways in the development of PCa should be investigated. These include an
examination of the role of epigenetics in the development of PCa and the mechanisms that
allow AR to tether to oncogenes’ promoters. Furthermore, the use of co-therapies to target
different oncogenic agents involved in PCa progression or continued activation of AR
could provide a better therapeutic than ADT. Research investigating the role of downstream
potent oncogenes is likely to yield more significant results than focusing on sole AR
repression. As we have shown, a therapeutic that focuses on sole AR repression as ADT
can also lead to the downregulation of critical tumor suppressors, like DAX-1. Because of
the intricacies of molecular biological pathways and the significant amount of ambiguity
and unknown cross-talk between proteins, the mechanism of PCa development and
progression is uncertain. The use of an aggressive response, like ADT, could trigger nonreversible effects within cells that could be one of the origins for CRPC.
Finally, the study of the interplay between AR, PR, and ER in hormone responsive
cancers is crucial. The understanding of the molecular mechanisms and their effects driven
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by these receptors can vary in the context of different cancers. In the same manner, the
effects of ER and PR activation, and the ramifications of these results in the context of PCa
have not been thoroughly addressed. The complete understanding of all mechanisms that
drive a cancer to develop and progress is an ongoing endeavor among scientists and
medical professionals. The findings in this thesis begin to shed light on the various
elements needed for a complete understanding of cancer development and progression.
Moreover, these results aim to create awareness of the complex aspects of cancer biology
and the influential role transcriptional repressors, like DAX-1, have in the progression of
cancer cells.
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